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Abstract 
Luteinising hormone-releasing hormone (LHRH), also known as gonadotropin-releasing 
hormone (GnRH) and luliberin, is a key hormone associated with controlling functions of 
reproductive organs in both males and females. Anti-LHRH vaccines can produce 
immunity against LHRH resulting in castration effects, which can be applied for 
contraception in animals or the treatment of hormone-dependent diseases. A self-
adjuvanting delivery system for peptide-based vaccines is a safe and effective approach to 
address the problem of toxic adjuvants used in animals and humans. Lipid core peptide 
(LCP) provides self-adjuvanting properties and is recognised to interact with specific Toll-
like receptors on antigen presenting cells. Lipidic adjuvant, in conjugation with polylysine 
or a carbohydrate core in a multiple antigen peptide (MAP) system, has shown significant 
contribution to enhance the immunogenicity of small antigens like peptides and these 
approaches of modification have been adapted to reder immunogenicity studies.  
 
One of the approaches is use carbohydrates to induce immunity is an effective and new 
strategy if the obstacles associated with poor quality of antibody response are overcome. 
Modified monosaccharaides such as glucose or galactose scaffold offer MAP system-like 
properties that provide attachment sites for conjugation of multiple identical epitopes. 
Moreover, different carbohydrate groups provide different orientations for the side chains. 
This structural conformation-related effect may augment immunity in vaccination. A 
carbohydrate-based anti-LHRH vaccine candidate was synthesised with a galactose 
scaffold. D-galactose was modified as a scaffold to provide conjugation sites for the 
attachment of four LHRH epitopes. However, due to low efficiency of the method, the 
synthesis resulted in a low yield of galactose scaffold, therefore sufficient final vaccine 
candidate was not achieved to be used in immunological studies.  
Another approache of modification uses three components to form four branched vaccine 
candidates –(1 [Th(K-LP)LHRH], 2 [LHRH(K-LP)Th], 3 [LHRH(K-Th)LP], 4 [Th(K-
LHRH)LP])– were designed and synthesised by assembling a promiscuous CD4+ T cell 
epitope (influenza HA2 light chain), a self-peptide LHRH, and an adjuvanting lipid moiety 
(2 × C16LAAs with 2 × Ser spacer) in different spatial arrangements. In vivo studies 
revealed effective anti-LHRH immunity was produced by all vaccine candidates with no 
need for coadministrstration of supplemental adjuvants. Furthermore, in vitro experiments 
revealed that the four compounds induced a significant direct antiproliferative effect (up to 
55%) on a LHRH receptor-positive prostatic cancer cell line, LNCaP, (p < 0.05). This effect 
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was shown to be weaker in the LHRH receptor-negative cell line, SKOV-3, (p > 0.05). 
Marked degenerative changes were observed in morphology and follicular development in 
the ovaries of immunised mice. There was a decrease in the number of healthy antral 
follicles and an increase in the number of degenerative antral and atretic follicles, 
approximately 30% higher in treated ovaries than in control ovaries. In light of these 
results, compounds 2, 3 and 4 are promising candidates for immunisation against the 
LHRH peptide. 
 
Last but not the least, a library of anti-LHRH vaccine candidates were designed using a 
MAP system, incorporating a lipopeptide system, and a combination of different lengths of 
LHRH epitope with a universal T helper epitope. Compounds synthesised using the MAP 
system demonstrated promising immunogenicity possibly through increasing contact with 
antigen presenting cells by multiple epitopes. Compounds were synthesised via solid 
phase peptide synthesis and azide-alkyne cycloaddition. This technique was used to 
overcome the problem of purification due to the high hydrophobicity of lipopeptide. Among 
all candidates, truncated LHRH-T helper epitope immunised mice demonstrated potential 
in vaccine development when the C-terminus of truncated LHRH was free in space.  
 
 
Overall, this project unravelled the ability of different applied synthetic strategies and 
delivery systems to stimulate anti-LHRH immune response, and contributes to the 
development of future immunocontraceptives or vaccines against hormone-dependent 
cancers.  
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Chapter 1: Introduction 
1.1  Luteinising hormone releasing hormone and its applications 
Luteinising hormone-releasing hormone (LHRH), also known as gonadotropi-releasing 
hormone, is secreted from the base of the hypothalamus and stimulates gonadotropic cells 
in the anterior pituitary gland to release luteinising hormone (LH) and follicle-stimulating 
hormone (FSH) [1,2]. LH and FSH in turn regulate the gametogenic and steroidogenic 
functions of the gonads (Figure 1.1). Vaccination against LHRH leads to anti-LHRH 
antibodies that neutralise LHRH and prevent the secretion of LH and FSH, resulting in 
immunocastration [3, 4]. This response has led to studies that used peptide-based LHRH 
vaccines for the treatment of hormone-sensitive cancers [2, 4, 5] or as 
immunocontraceptives [2, 6]. The contraception time that anti-LHRH vaccine induced 
depends on course of vaccination, dosage and animal speceices. Finstad et al. showed 
that anti-LHRH antibodies in sexually mature intact dogs last 20 weeks, over 90 weeks in 
Baboon monkeys in their study [1]. 
 
Figure 1.1. Control route of sex hormones 
1.2 Contraceptive vaccines 
With the increasing human population, food, water and resource shortages are always of 
public concern. Additionally, excessive wild animal proliferation causes environmental 
issues such as damaging the ecosystem, hindering the growth of forests, and spreading 
Hypothalamus
Pituitary
LH and FSH
LHRH
Testosterone Oestrogens and 
Progesterone
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+
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+
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animal-to-human transmitted diseases. Wandering cats and dogs are seen as a societal 
concern. Therefore, animal birth control is an adequate and effective way to address these 
problems. Immunocontraception has been proposed as an acceptable, effective and 
achievable way to control the wild animal population. It is also an alternative to traditional 
castration methods such as surgery and chemical castration. Surgical castration is widely 
used in domestic animals to achieve certain purposes such as removing body odour (boar 
taint) to improve meat quality and reducing animal’s aggressive behaviours for better 
management. Nowadays, public awareness of animal welfare has improved. Some studies 
of chemical castration have shown side effects in the reproductive organs such as swelling 
and inflammation [2]. Hence, immunocontracptive castrations can prevent animals’ 
suffering from adverse effects associated with chemical castration. The mechanism of 
immunocastration is through utilising immunity against endogenous sex hormones in the 
body [3]. In addition to various immunological factors such as the type of antigen that 
influences the development of a commercially successful vaccine for animals, formulation 
and delivery aspects are also important. The latter includes the choice of route of 
administration, the need for a vector or specific delivery system, and the nature of the 
target animal population and their habitat [4]. Several immunocontraceptive vaccines have 
been classified based on their targets such as anti-sperm vaccines, anti-zona pellucida 
(ZP) vaccines, anti-human chorionic gonadotropin (hCG) vaccines and anti-LHRH 
vaccines and these will be discussed in the following sections. 
1.2.1 Contraceptive vaccines targeting gamete function 
Vaccines targeting gamete function against sperm antigens and zona pellucida (ZP) are 
among the different possible approaches towards immunocontraception. Sperm has been 
found to possess auto- and isoantigen properties, which are able to induce antibody 
production in males and females [5]. The antibody induced by sperm is known to inhibit 
fertilisation in vivo. Fertilisation and fertility have been shown to be blocked by anti-sperm 
antibodies (ASA) both in vitro and in vivo [6].  In a clinical trial in 1932, immunisation with 
sperm stimulated the development of anti-sperm antibodies which led to infertility [7]. 
However, the entire spermatozoon is not antigen-specific due to sharing the same 
antigens with various somatic cells [8]. Targeting sperm requires sperm-specific antigens, 
which means that only a certain part of sperm can be used to produce ASA [5].  
 
The ZP matrix that surrounds the mammalian oocyte plays a critical role in the recognition 
and binding of sperm to the oocyte during fertilisation. Therefore, it can be targeted for the 
development of contraceptive vaccines [5]. The ZP is composed of three glycoproteins, the 
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vital function of which is to provide a binding site for sperm as well as prevent polyspermy. 
A variable degree of conservation has been shown in certain regions of the cDNA of the 
ZP glycoproteins from different species. Therefore, there is cross-reactivity between the 
anti-ZP antibodies produced by a particular species to a different one. The 
immunocontraceptive potential of ZP glycoproteins isolated from a native porcine source 
was proven by some research groups [9, 10]. However, some disadvantages of utilizing 
ZP glycoproteins including limited amounts of ZP glycoprotein obtained from native 
sources, batch-to-batch variations in the quality of the purified product, and risk of 
contamination with other ovarian-associated proteins. But recombinant ZP proteins have 
proven their potential in antifertility of inbred mice and could address these difficulties [11]. 
1.2.2 Contraceptive vaccines targeting gamete outcome  
Vaccines targeting gamete outcome primarily focus on hCG, which plays an important role 
in reproduction and is used clinically in the treatment of infertility. Following fertilisation, 
hCG that is synthesised and secreted by the growing blastocysts (subsequently placenta), 
is considered to be critical to support the corpus luteum for the maintenance of conception 
[12]. Thus, it is a potential target to be exploited for the development of contraceptive 
vaccines. Talwar et al. revealed that the first birth-control vaccine against HCG in Phase II 
clinical trials successfully prevented sexually active females from pregnancy [13].  
1.2.3 Contraceptive vaccines targeting gamete production 
LHRH is a decapeptide identified and was firstly applied as vaccine by Schally and co-
workers in 1971 [14]. This peptide plays a vital role in controlling the release of sex-related 
hormones, LH and FSH. Vaccination against LHRH, leads to anti-LHRH antibodies that 
neutralise LHRH and prevent the secretion of LH and FSH, resulting in an 
immunocastration condition [14, 15]. The synthetic LHRH was dissolved in 0.9% NaCl 
solution mixed with 50% polyvinylpyrrolidone and was emulsified with Freund’s Complete 
Adjuvant (CFA) [16]. In this report a significant castration effect and the potential of LHRH 
vaccine to control functions of reproductive organs in males and females was 
demonstrated. Thus far, the development of potential LHRH vaccines has been hindered 
by a number of obstacles [17]. Due to having weak immunogenicity, a carrier protein or a T 
helper epitope is required for LHRH to elicit a potent immune response [17]. Similar to 
many peptide-based vaccines, anti-LHRH vaccines require adjuvants to give effective 
immunity [18]. Several carrier proteins or adjuvants have been examined with LHRH in a 
large number of domestic and wild animals [19-24]. However, a range of local and 
systemic side effects hinder the clinical use of adjuvants both in animals and humans [25-
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27]. For instance, CFA has been linked with local inflammation and granulomatous 
reaction at the site of injection. It may also cause chronic inflammation, skin ulceration, 
local abscess or tissue sloughing [28]. Currently, several anti-LHRH vaccines have been 
commercialised and are approved for use in domestic animals, for example, pigs, bulls, 
mares and rams. Improvac is proven to be safe for use in pigs. It contains synthetic LHRH 
which is chemically conjugated to a large protein and is formulated with an aqueous non-
oil based adjuvant [29]. Improvac coadministered with porcine somatotropin was shown to 
increase food intake and reduce fat deposition in tissue in pigs [29]. GonaCon® is another 
vaccine on the market. The vaccine structure consists of synthetic LHRH sequence 
conjugated to keyhole limpet haemocyanin (KLH) mixed with CFA [30]. Two injections 
elicited a one-year long immune response. It has now proven effective for use in wild 
animals such as white-tailed deer, California ground squirrels, Norway rats, feral cats and 
dogs, domestic and feral swine, wild horses, and elk [22]. Besides its application as a 
contraceptive, the anti-LHRH vaccine may also be used in the treatment of prostate 
cancer. Following clinical studies in India, Austria and the UK, the safety of LHRH linked to 
diphtheria toxoid (DT) vaccine was confirmed in prostate carcinoma patients. These 
studies further showed that testosterone declined to castration levels with concomitant 
decline of Prostate Specific Antigen (PSA) in patients generating adequate antibodies. 
This was a significant clinical benefit to patients [31]. 
1.2.3.1 Synthetic anti-LHRH vaccines 
Chemical synthesis of LHRH is advantageous because it allows chemical modifications of 
the peptide. For instance, substitution of glycine at position 6 with D-lysine，which renders 
further conjugation in the middle of the sequence [24, 32, 33]. Conjugation of LHRH to 
carrier proteins such as tetanus toxoid (TT) or DT as vaccine has been trialled in several 
animal and human studies [31, 34]. In addition, different structural modifications of anti-
LHRH were made to improve immunogenicity of the construct, for example, insertion of 
lipopeptide dipalmitoyal-s-glyceryl cysteine between LHRH and a T helper epitope of 
influenza virus haemagglutinin has shown its efficacy to confer an antifertility to BALB/c 
female mice [35].  
1.2.3.2 Recombinant anti-LHRH vaccines 
Except for chemical ligation of LHRH to a carrier protein, recombinant protein expression 
is an effective approach to coexpress LHRH and carrier protein as one moiety. This 
method is considered to be more economic in large-scale industrial production. A number 
of research teams have applied this technique in their development of anti-LHRH 
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vaccines. Hsu et al. (2000) expressed a recombinant protein containing 12 copies of 
LHRH with a carrier from the receptor-binding domain of Pseudomonas exotoxin A. 
Rabbits immunised with this vaccine showed significant ovarian atrophy [36]. Talwar et al. 
showed that coexpression of four or five selected T cell specific epitopes with four or five 
copies of LHRH generated anti-LHRH antibodies in all animals, which caused the decline 
of testosterone to castration levels. Using four to five different T helper epitopes was 
proposed to enable communication with major histocompatibility complex (MHC) of 
subjects with genetic diversity [37]. Finstad et al. (2004) also developed a similar strategy 
by conjugating synthetic LHRH to four promiscuous T cell epitopes from recombinant 
protein expression [38].  
1.3 Vaccine Adjuvants 
An adjuvant is an immune response stimulator used in vaccine, which boosts the host’s 
immune response and recognition of antigens. The adjuvant also increases the efficacy of 
vaccine by reducing the amount of antigen required. In subunit vaccine where minimum 
components of pathogen are used as antigen, a strong immunostimulatory is often 
required to increase its immunogenicity.  
LHRH is a decapeptide and endogenous hormone, which has been incorporated as an 
antigen in anti-LHRH vaccines [39]. Nontheless, in the absence of an adjuvant the LHRH 
peptide does not produce a potent immune response as it is a self-hapten and is highly 
conserved. Also, the LHRH sequence does not contain any T helper epitope and hence 
does not induce a T cell response. Attempts were made in the 1970s to induce antibody 
production against LHRH by coadministering the peptide with CFA. However, these 
attempts proved unsuccessful in producing high antibody titres [40]. Modification of the 
vaccine structure is necessary in order to improve the efficacy of anti-LHRH vaccines. 
Selection of a suitable adjuvant and a carrier system, the molar ratio of the carrier and 
hapten, and conjugation methods are critical for developing an optimal vaccine against 
small peptides [41, 42]. Mechanism and classification of adjuvants will be described below. 
1.3.1 Mechanism of adjuvants 
The vaccine antigen is taken up by immature dendritic cells (DC) via two approaches: 
receptor-mediated endocytosis or fluid-phase pinocytosis. Through these methods, 
antigens are internalised by DCs which promotes their maturation. This maturation may 
occur with different kinds of antigens such as the components of microorganisms [43, 44], 
or vaccine adjuvant [45]. Microbial components and inflammatory chemokines mediate the 
recruitment of immature DCs, which migrate from peripheral vessels to draining lymph 
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nodes. For effective antibody production, persistent release of antigen from the injection 
site provides enough time for antigen present in the draining lymph node to be taken up by 
follicular DCs [46]. Water-oil emulsion injections allow antigens and adjuvant to form a 
depot locally and gradually release the antigen in a sustained way [47]. Microorganism-
sourced adjuvants provide their adjuvanticity via recognition by pathogen recognition 
receptors (PRRs) existing on the surface of antigen-presenting cells (APCs). Without extra 
stimuli from conserved microbial structures, that are also known as pathogen-associated 
microbial patterns (PAMPs), to the PRRs on immune cells, the presentation of a specific 
antigen is not able to induce an effective immune response. PRRs are expressed by 
conserved genes. They are like a database storing the identifications of variable 
pathogens encountered by immune cells. With these identifications, PRRs can promote a 
co-stimulatory response with antigen to generate an effective immune response [48, 49]. 
 
These factors threaten cells but do not cause cell apoptosis. Adjuvant is recognised as a 
source of danger signal to cells. Like the danger signals sourced from damaged and 
infected cells. The immune cells detect these signals and trigger immune responses [50]. 
Cytokines are communicators that cells use with other cells for induction of an immune 
response. Adjuvant as a danger signal can induce inflammation at the injection site to 
trigger cells releasing cytokine in order to respond to the inflammation immediately [51]. An 
ideal adjuvant for peptide-based vaccines is one that induces both cellular (T helper, Th1), 
which is a CD4 immune response mainly to promote maturation of B cells for specific 
antibody production, and humoral (Th2) immune responses for maturation of macrophages 
that diminish pathogens by phagocytosis [52]. Foreign invasive immunogens in vivo trigger 
cells to release cytokines, thus leading to Th1 and Th2 immune responses.  
1.3.2 Classification of adjuvants 
1.3.2.1 Mineral-based adjuvants 
Mineral-based adjuvants, for example, aluminium hydroxide and aluminium phosphate, are 
the most commonly used components of prophylactic vaccines in humans [53]. The alum-
based adjuvants are known to induce potent Th2 immune responses but less Th1 immune 
responses. However, recent studies have revealed the high toxicity of aluminium for 
neurons in early stages of brain development in humans and experimental animals. In 
adult humans, long-term exposure to aluminium causes cognitive dysfunction and 
autoimmune responses [54]. Alternatives to alum salt-based adjuvants are calcium, iron 
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and zirconium salts, which are less potent in adsorption of antigens for efficient production 
of antibodies than alum-based adjuvants [55, 56].  
1.3.2.2 Oil-based adjuvants 
Oil-based emulsions such as saponins can induce stronger cellular immune response than 
alum-based adjuvants, which is particularly required for the effect of some vaccines [25]. 
Quil A is a saponin that has been commonly used in veterinary vaccines. It is restricted for 
use in humans because it causes severe haemolysis [57].  The most potent adjuvant used 
in veterinary vaccine formulations is CFA containing inactivated or dry mycobacteria (e.g. 
M. tuberculosis) coated on the surface of water droplets in oil phase [58]. CFA is only 
permitted for use in animals due to its severe human toxicity. Side effects include local 
inflammation and granulomatous reaction at the side of injection. These water-in-oil or oil-
in-water type adjuvants act like a depot at the injection site to gradually release antigen 
[59]. They also promote plasma cells for antibody production. The application of this type 
of adjuvant is only allowed in terminally-ill cancer patients [27].   
1.3.2.3 Microbial component-based adjuvants 
Bacterial products are used as adjuvants. Peptidoglycan and lipopolysaccharide, sourced 
from Gram-negative bacteria, are able to enhance immunogenicity [60]. Virulence and 
ability to revive to the pathogenic form of these adjuvants causes concerns in human use 
vaccines [61].   
1.3.2.4 Immunostimulatory complexes 
Immunostimulatory complexes (ISCOMs) including cytokines, interferon-γ (IFN-γ) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) have been seen as novel 
adjuvants in the past decade. IFN- γ is able to enhance cellular immune response through 
a series of mechanisms such as recruiting APCs [62, 63]. GM-CSF is able to enhance the 
primary immune response and also to recruit APCs. Liposomes are a synthetic 
biodegradable vehicle that can encapsulate antigen for delivery to APCs. Liposomes are 
well-accepted in vivo and allow easy controlled release of antigen [64]. However, factors 
like modification, methods of preparation and constitution significantly affect the efficacy of 
liposomes [65]. 
1.4 Peptide-based subunit vaccine 
Peptide-based vaccines utilise minimal components as a specific antigen necessary to 
stimulate an effective immune response in order to avoid potential harmful virulence parts 
from the whole pathogens [66]. LHRH is a short decapeptide naturally existing in vivo. It 
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does not possess any pathogenic properties. Thus, to increase its immunogenicity, 
structural modification is a major requirement to build an anti-LHRH vaccine, for example, 
attachment of a promiscuous T helper epitope, multiple antigen-presenting systems, and 
self-adjuvanting lipidic moiety. 
1.4.1 T helper epitope 
T helper epitope is a peptide allows APC to display on an MHC class II and bind to 
immature CD4+ T cell, which leads to the maturation of the T helper cells. T helper cells 
are important for maturation of T cells to eliminate intracellular pathogens, and maturation 
of B cells to produce specific antibodies. T helper epitope enables conjugation with a 
target antigen via chemical ligation or recombinant protein expression technique. The 
combination of two specific peptides allows the whole peptide structure to be receptor-
specific [67]. Prior to human clinical trials, preclinical studies in mice have clearly shown 
that MHC should be taken into account in the selection of a T helper epitope [67]. LHRH 
itself is an endogenous hormone and is recognised as a hapten. Development of an anti-
LHRH requires it to be conjugated to a carrier protein or a promiscuous T helper epitope to 
enhance immunogenicity [68]. Large inactivated toxins such as TT, DT and its nontoxic 
mutant, CRM197, are used as carriers in vaccines to develop strong immune responses. 
Thus, traditional vaccine candidates are conjugated to a carrier protein, such as TT, 
Neisseria meningitides group B outer membrane complex (OMPC), DT, or CRM197, KLH 
[22], thioredoxin and ovalbumin [69]. However, this approach suffers from several 
shortcomings. Conjugation of antigen with a carrier protein is not site-specific leading to 
variable levels of antigen presentation. Furthermore, it is difficult to characterise the 
construct and to maintain batch-to-batch consistency specifically for large-scale production 
[68]. The solution is to use a promiscuous or universal Th peptide epitope that binds to a 
few or most human leucocyte antigen class II (HLAII) molecules. Therefore, the whole 
human population responds to a vaccine [70]. Several studies have shown variable T 
helper epitopes from influenza haemoglutinin HA2 and canine distemper virus fusion 
protein for conjugation with LHRH and induced significant specific antibody production and 
castration effect in inbred mice (BALB/c) [35, 71]. Delves and Roit’s group employed 
Mycobactrium tuberculosis heat shock protein to conjugate with a modified LHRH 
sequence (D-lysine replaced the sixth amino acid providing a free amino group for 
conjugation site) [32]. Zeng et al. conjugated the same modified LHRH sequence with 
albumin in a vaccine structure, which led to castration of pigs [33]. Zhang et al. employed 
recombinant protein expression techniques to express ovalbumin with 4-7 copies of 
repetitive LHRH sequence in one construct [72]. Ferro et al. revealed that either the C-
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terminal or the N-terminal of a modified LHRH peptide conjugated to a carrier protein 
produced different levels of antibody production and binding avidity of LHRH. Anti-LHRH 
antibodies induced from a vaccine containing the N-terminal of a modified LHRH 
(CHWSYGLRPG-NH2) conjugated to a TT gave high LHRH binding avidity antibodies and 
also exerted their effect on male reproductive organs and concentration of testosterone, 
LH and FSH. However, modification of the C-terminus gave high antibody titres but had 
less effect on reproductive organs and sex hormones. In addition, Ferro et al. also proved 
that dimerization of LHRH peptide in vaccines gave better immune response than 
monomers [72-74].  
1.4.2 Branched vaccine structures 
Lysine is a versatile amino acid when used as a building block in synthetic peptides. It 
provides two amine groups and a carboxylic group allowing for branch and/or dendrimer 
construction. Charalammbos et al. mentioned that both a B cell epitope and a T cell 
epitope have different sites on one vaccine structure, which provides effective 
immunogenicity [75].  It was revealed that a chimeric peptide structure that contains a T 
cell epitope and a B cell epitope is an effective strategy against measles [75]. The T cell 
epitope from surface glycoproteins of measles virus showed assistance to the B-cell 
epitope, an epitope from haemagglutination (the other surface glycoprotein) in B cell 
specific antibody production. This research also revealed that the orientation of both the T-
cell epitope and the B-cell epitope affects immunogenicity and the affinity of antibodies 
[75]. In terms of antigen presentation, branched structures appeared better immune 
responses than linear structures [76].  
The advantage of one construct containing multiple identical epitopes is the ability to 
increase the chances of interaction with APCs. A branching core with multiple conjugation 
sites allows the attachment of multiple uniform epitopes to increase the portion of antigen 
in the vaccine construct. Tam’s study showed a multiple antigenic peptide (MAP) system 
(Figure 1.2) containing a polylysine branching core possessing free terminal amines to 
which multiple identical epitopes were attached [77].  
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Figure 1.2. An example of MAP system: polylysine 
1.4.3 Lipidic self-adjuvanting system   
Bacterial cell walls contain lipoproteins (LP) as one of their components, for example, 
Braun’s lipopeptide from Escherichia coli. Bacterial LP consists of a S-glycerylcysteine 
involving di-O-acylated glycerol moiety. The cysteine in the structure is attached to the 
amino-terminus of various polypeptides (Figure 1.3).  
  
Figure 1.3. An example of bacterial lipoprotein, Braun’s lipopeptide from Escherichia 
coli [78]. 
Lipidation has been shown to improve peptide vaccines by attaching to cell membranes. It 
enhances peptide hydrophobicity, which increases permeability of biological membranes 
[79]. Lipidation also improves the metabolic stability of peptides by protecting them from 
enzymatic degradation [80]. Different modifications of lipidic adjuvant have demonstrated 
that utilising glycine as spacer molecules, or increasing the length of the lipoamino acid, a 
diastereomeric molecule possessing alkyl side-chains and amino acid-like structure and 
has two diastereomers, could enhance an immune response against the attached peptide 
antigens [81]. Studies from our research group proved that a vaccine against Group A 
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Streptococcus (GAS) using lipid core peptide, with three lipoamino acids and glycine or 
serine for spacers, as a self-adjuvanting system successfully induced high antibody titres 
[82-84]. In addition, Goodwin’s studies also revealed anti-LHRH vaccine candidates using 
lipidic self-adjuvanting molecules with polylysine attached to the LHRH epitope and a ram-
specific T helper epitope elicited a potent immune response [85]. The structure-activity 
relationship investigation of these self-adjuvanting constructs confirmed the importance of 
including both B and T helper epitopes to obtain an effective induction of systemic 
Immunoglobulin G (IgG) against LHRH. In this study it was also shown that candidates 
that contained multiple copies of the LHRH dimer were able to induce significant immune 
response in mice without the need for additional helper epitopes [86]. This was a 
significant finding because sometimes it is a challenge to select a helper epitope, 
particularly when cross-species immunity is of concern in the development of a vaccine 
candidate [87, 88]. 
1.4.4 Carbohydrate core 
Carbohydrate is another versatile molecule in the development of synthetic peptide 
vaccines. Modification of the functional groups of the carbohydrates provides a number of 
attachment sites for conjugation of multiple identical epitopes [89]. Different carbohydrates 
(Figure 1.4) afford different spatial arrangements for the peptide epitopes, some of which 
may result in better recognition by immune cells. It has been suggested that carbohydrate 
carriers reduce degradation of the attached peptide antigens [90]. Similar immune 
responses were found when using polysine dendrimers or carbohydrate (glucose) as a 
branching core in vaccine construct [90]. 
 
Figure 1.4. Chemical structure of D-glucose and D-galactose. 
1.5 Evaluation of effects of LHRH vaccine candidate on the morphology and 
function of sexual organs 
Neutralising endogenous LHRH with anti-LHRH antibodies results in a series of effects on 
reproductive organs. Numerous measurements are widely used in most research to 
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determine these effects. These included measuring the concentration of sex-related 
hormones, for example, LH, FSH, androgen (testosterone) and oestrogen (oestradiol, 
progesterone). In many studies using male animal models, the degeneration of sexual 
organs, mainly testis, has been examined to investigate the effectiveness of anti-LHRH 
vaccines or LHRH agonists. Furthermore, the level of androgens, mainly testosterone, has 
been detected to determine the castration effect of the compounds [91-94]. Microscopic 
morphological changes are commonly seen in both testis and ovaries. Degeneration of 
testicular tissue includes decrease in the number of spermatids, shrinkage of Sertoli and 
Leydig cells, and hyalinisation of peritubular connective tissue. Size and weight of sexual 
organs and sperm count per gram, were also suggested to be supportive information 
towards detection of atrophy. In female models, degenerative changes in ovary tissue 
include disorganised granulosa cell layers, shrunk ooplasm, less number of antral follicles 
and a high ratio of atretic follicles [95, 96].   
 
Seghatoleslam et al. demonstrated 80-90% reduction in testosterone and decrease in 
sperm count in Sprague Dawley rats immunised by a conjugate of LHRH with either KLH 
or TT [97]. Malmgren et al. observed degeneration of spermatogonia and spermatocytes in 
testis, in addition to decreased levels of circulating testosterone and oestrone sulphate in 
an immunised stallion with a LHRH-based vaccine conjugated to bovine serum albumin 
[98]. Ulker et al. treated rams with LHRH fused with ovalbumin which showed 
morphological changes in testis and significant reduction in the level of testosterone [99]. 
Song et al. carried out a study using a recombinant protein expressing LHRH with a 
heatshock protein to immunise BALB/c mice which led to reduced follicular development in 
their reproductive organs [94]. This recombinant vaccine construct also showed an 
inhibitory effect on mammary tumour cells [94]. Immunisation of ICR male and female mice 
with a genetic vaccine encoding LHRH with five T helper epitopes in one sequence, 
effectively reduced testosterone to 75% lower than the baseline and impaired testicular 
function in male mice and suppressed folliculogenesis in female mice, thus inhibiting 
fertility in both mouse groups [100]. Active immunisation with LHRH-ovalbumin, 
coadministered with CpG oligodeoxynucleotide, led to reduction in the number of corpus 
luteum in vaccinated heifers[101]. Besides histopathological examination, investigating the 
fertility of vaccinated animals is an index to determine the efficacy of anti-LHRH vaccines. 
Immunocontraception of feral swine with 2 mg of LHRH-KLH along with AdjuVacTM 
resulted in a complete control of fertility in 9 female swine after 36 weeks. Only 20% of the 
1,000 µg-treated females became pregnant in this study [102]. A single dose of 
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GonaConTM could completely control fertility in wild boars with detectable anti-LHRH 
antibody titres in all female animals up to six years after vaccination[103].  
 
1.6 Conclusion 
This chapter provides the background and relevant sections toward development of anti-
LHRH vaccines. The LHRH epitope has its advantage as a short peptide. Yet, to elicit 
potent immunogenicity, structural modifications are required due to vaccine with limit of 
toxic adjuvants to human, a prerequisite of T cell epitope for effective antibody production. 
Chemical molecular conjugation of lipidic adjuvant, polylysine and carbohydrate as a 
multiple antigen-presentation system has shown the enhancement of immunogenicity. 
Synthesis and characterisation of an anti-LHRH vaccine based on a carbohydrate scaffold 
are presented in Chapter 2. A library of synthetic anti-LHRH vaccine candidates based on 
these strategies has been made. Four characterised branched anti-LHRH vaccines are 
examined for use in vitro and in vivo (Chapter 3). Utilisation of MAP in anti-LHRH vaccine 
structures is presented in Chapter 4. The conclusion of this project is presented in Chapter 
5. The ultimate goal of this study is development of lipopeptide self-adjuvanting system to 
induce immunogenicity against LHRH, without the need to use external adjuvants. 
Chemical modifications were made on the native structure of the peptide using different 
spatial arrangements to achieve this aim. 
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Chapter 2  
Synthesis and characterisation of 
an anti-LHRH vaccine candidate 
with a modified galactose scaffold 
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Chapter 2: Synthesis and characterisation of an anti-LHRH vaccine 
candidate with a modified galactose scaffold 
2.1 Introduction 
D-Glucose and D-galactose have shown their potential in vaccine candidates against GAS 
[90]. Both carbohydrate molecules as a scaffold with a lipid core peptide (tree copies of 
lipoamno acids) in GAS vaccine candidates were shown to induce potent immune 
response that was comparable to the positive control [90]. The strategy of using a 
carbohydrate core was therefore applied to the synthesis of anti-LHRH vaccine candidates 
in this study. An anti-LHRH vaccine candidate was synthesised with D-galactose, as a 
scaffold modified to provide conjugation sites for the attachment of four LHRH epitopes 
and a lipopeptide containing two diastereomeric lipopoamino acids (Figure 2.1). This 
vaccine candidate allows direct comparison of different carbohydrate-based anti-LHRH 
vaccine candidates. 
 
Figure 2.1. Structure of the anti-LHRH vaccine candidate containing lipopeptide, 
linker, galactose and LHRH. 
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2.2 Materials and methods 
General 
Dimethylformamide (DMF), trifluoroacetic acid (TFA), piperidine, methanol (MeOH), 
dichloromethane (DCM), silica 60 mesh, ethyl acetate and hydrogen chloride (HCl) 37%, 
hydrogen bromide/acetate acid 30% and analytical grade acetonitrile were purchased from 
Merck Bioscience (Kilsyth, VIC, Australia). O-Benzotriazole-N,N,N’,N’-tetramethyl-
uronium-hexafluorophosphate (HBTU) and Boc-amino acids are purchased from 
Mimotope (Clayton, VIC, Australia). p-methylbenzhydrylamine resin (pMBHA) was 
purchased from Peptides International Inc. (Kentucky, USA). N,N-Diisopropylethylamine 
(DIPEA) used for activation of amino acids was sourced from Sigma Aldrich (Castle Hill, 
NSW, Australia). Diethyl acetamidomalonate, 1-bromotetradecane, benzyl alcohol, 4-
dimethylaminopyridine (DMAP), sodium azide, celite, 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU), acrylonitrile, magnesium sulphate, cobalt chloride hexahydrate, di-tert-butyl 
dicarbonate, Sodium borohydride, D-(+)galactose were purchased from Sigma Aldrich 
(Castle Hill, NSW, Australia). D-tert-butydicarbonate (Boc2O) was sourced from Ak 
Scientific (Union City, CA, USA). Dioxan, acetic anhydride (Ac2O) and acetic acid (AcOH) 
were purchased from Ajax Finechem (NSW, Australia). Sodium sulphate, sodium 
bicarbonate and sodium chloride were purchased from Chem-supply (Gillman, SA, 
Australia). LRC 50H resin was sourced from Hopkin & Willams LTD (Essex, England).  
 
Equipment 
Peptides were characterised by electrospray ionisation mass spectrometry (ESI-MS) on a 
PE Sciex API3000 triple quadrupole mass spectrometer (Framingham, MA, USA) using a 
mixture of solvent A1 (0.1% acetic acid (AcOH) in water) and B1 (0.1% AcOH in 9:1 
acetonitrile/water) at 0.05 mL/min.  A Varian Cary 50 Bio UV/vis spectrophotometer (US) 
(λ = 570 nm) was used for absorbance measurements. Reverse-phase analytical HPLC 
(RP-HPLC) was performed on an Agilent 1100 (US) system fitted with a binary pump, auto 
sampler, and a UV detector set to a wavelength of 214 nm. Preparative RP-HPLC was 
performed on a Shimadzu instrument (Kyoto, Japan; LC-20AT, SIL-10A, CBM-20A, SPD-
20AV, FRC-10A) in linear gradient mode using 20 mL/min flow rate with detection at 230 
nm.  Crude peptide purification was performed with solvent A2 (0.1% TFA in water) and 
solvent B2 (0.1% TFA in 9:1 acetonitrile/water) on a Vydac preparative C4 column 
(214TP1022; 10 µm, 22 x 250 mm). An H-cube hydrogenator was purchased from 
ThalesNano Nanotechnology Inc., (Budapest, Hungary). 
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2-tert-Butoxycarbonylaminohexadecanoic acid (Boc-C16) 
 
 
Figure 2.2. Synthesis of (2-(R.S)-[(tert-butoxycarbonyl) amino)- hexadecanoic acid 
(Boc-C16). 
Boc-protected 16-carbon lipoamino acid (Boc-C16) (Figure 2.2) was synthesised 
according to a published method [104]. A solution of sodium ethoxide was made by mixing 
sodium (1.15 g, 0.05 mol) and ethanol (39.5 mL, 0.71 mol) together. Diethyl 
acetamidomalonate (10.9 g, 0.05 mol) and 1-bromotetradecane (14.5 mL, 0.07 mol) were 
added to sodium ethoxide to reflux for one day at 79°C. After reflux, the mixture was 
cooled to room temperature, ice cold water was added for filtration and wash The crude 
product was dried in a desiccator and refluxed with 35% HCl (60 mL) and 
dimethylformamide (7 mL) for 3 days. The mixture was then cooled to room temperature 
for further addition of 28% ammonium solution (60 mL), which was poured into the flask 
gradually and stirred for 5 min. After neutralisation with ammonium solution, ice-cold water 
was added to the mixture, and the mixture then filtered, and washed with more ice-cold 
water. The filtrate was desiccated to obtain 2-(R,S)aminohexadecanoic acid hydrochloride.  
2-(R,S)aminohexadecanoic acid hydrochloride was dissolved in alkaline conditions by 
adding it to cold sodium hydroxide solution (3.38 g, 0.084 mol, 100 mL). Boc2O (9.22 g, 
0.042 mol) was first dissolved in dioxane (100 mL) and then poured into the mixture to 
react with 2-(R,S) aminohexadecanoic acid hydrochloride for 3-5 h. After the reaction was 
completed, evaporation was carried out to remove the dioxane. To adjust the pH to 3, HCl 
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(5%) was added to the aqueous phase. EtOAc (2 x 300 mL) was mixed with the pH-
adjusted aqueous solution for extraction and then washed with brine. The organic phase 
(EtOAc) was filtered and dried over MgSO4. After evaporation of EtOAc, acetonitrile (5-10 
mL) was added to the resultant oil. The mixture was cooled to 0ºC and the resultant white 
solid was scratched from the flask. The white solid was then filtered and rinsed with a 
small amount of acetonitrile (5 mL) to obtain the final product (2-(R.S)-[(tert-
butoxycarbonyl) amino)-hexadecanoic acid, Boc-C16 (yield = 6.1g, 40%,). ESI-MS: 316 
[M+H]+. 1H NMR (300 MHz, CDCl3): 0.86(t, 3H, J = 7.0 Hz, CH3), 1.24 (m, 16H, 8 x CH2), 
1.43 (s, 9H, CMe3), 1.56-1.85 (m, 2H, beta-CH), 4.30-4.20 (m, 1H, alpha-CH), 4.93 (d, 1H, 
J = 7.1 Hz, NH).  
 
Succinic monobenzyl ester (linker) 
 
Figure 2.3. Synthesis of succinic acid monobenzyl ester 
Succinic acid monobenzyl ester was synthesised as a linker between the lipidic adjuvant 
and the carbohydrate core, according to a method from the literature (Figure 4.3) [105]. A 
mixture of succinic anhydride (1.00 g, 10.0 mmol), benzyl alcohol (860 mL, 8.30 mmol), 
and DMAP (1.02 g, 8.30 mmol) in DCM (30 mL) was stirred for 18 h at room temperature. 
After this time, a solution of 5% Na2CO3 was poured into the reaction mixture and the 
layers were separated. The aqueous layer was acidified with 1 M HCl and extracted with 
EtOAc. The EtOAc layer was washed with brine, dried over Na2SO4, and evaporated to 
afford colourless oil. Yield (1.05 g, 60.7%): 1H NMR (CDCl3) δ: 7.37- 7.34 (m, 5H), 5.15 (s, 
2H), 2.71-2.68 (m, 4H).  
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Figure 2.4. Synthesis of galactose core 
D-galactose was used as a carrier to form the attachment between the lipidic adjuvanting 
moiety and four copies of the possible LHRH peptide epitope (Figure 2.4). The synthesis 
procedure was based on a study by Simerska et al. [90].  
 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl Azide #1  
Ac2O (26 mL, 280.5 mmol) was added to a flask containing D-galactose (10 g, 55.5 mmol). 
The mixture was cooled using an ice bath. Then hydrogen bromide (HBr) / AcOH (30%, 
14.85 mL, 55.0 mmol) was added dropwise to the mixture causing an immediate 
exothermic reaction. The reaction mixture was stirred at room temperature until the 
solution was clear. Additional HBr/AcOH (30%, 14.85mL, 110 mmol) was added, and the 
mixture stirred for another 2 h at room temperature. The reaction was monitored by 
analytical thin layer chromatography (TLC) (hexane/EtOAc 1:1). When the reaction was 
complete, the solvents were removed under reduced pressure. The resulting solid was 
dissolved in acetone (50 mL) and a solution of sodium azide (1.03 g; 15.84 mmol) in H2O 
was added. The reaction mixture was stirred at room temperature and monitored by TLC. 
Solvent was then evaporated at reduced pressure and the product crystallised 
spontaneously. The solid was suspended in water, filtered and washed with water. 
Recrystallization from ethanol afforded a pure product. Yield (2.8 g, 57.43%). TLC: Rf = 0.8 
(6:4 Toluene/EtOAc). ESI-MS: (C14H19N3O9, 373.1121) m/z = 374.1[M + H+]. 1H NMR (300 
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MHz, CDCl3): 5.42 (dd, 1H, CH, J = 3.3 Hz), 5.03 (dd, 1H, CH, J = 10.3, 3.3 Hz), 5.17 (dd, 
1H, CH, J = 8.6, 10.4 Hz), 4.6 (d, 1H, CH, J = 8.8), 4.16 (m, 1H, CH), 4.02 (m, 1H, CH).  
 
β-D-galactopyranosyl Azide #2 
Compound 1 (2.8 g, 75 mmol) was dissolved in dry MeOH. Sodium (1-2 g) was added into 
the suspension immediately. The reaction was then monitored by TLC (EtOAc/MeOH/H2O). 
After the reaction was finished, LRC 50H resin was added to neutralise the mixture to pH 7. 
The mixture was filtered through Celite and evaporated under reduced pressure. Final 
product 2 was obtained through recrystallization from a mixture of ethanol and acetonitrile. 
Rf: 0.3 (8:1:0.3 EtOAc/MeOH/H2O). Yield (1g, 64%). 1H NMR (MeOD): 4.43 - 4.40 (m, 1H, 
CH), 3.85 - 3.80 (m, 1H, CH), 3.77 - 3.67 (m, 2H, CH2), 3.62-3.58 (m, 1H, CH), 3.52 - 3.41 
(m, 2H, CH x 2).  
2,3,4,6-Tetra-O-(cyanoethyl)- β-D-galatopyranosyl Azide #3 
DBU (0.4 mL, 2.6 mmol) and freshly distilled acrylonitrile (3.5 mL, 53.1 mmol) were mixed 
with galactopyranosyl azide (1 g, 48.7 mmol) in dry acetonitrile (25 mL), stirring at room 
temperature. Additional portions of DBU and acrylonitrile were added after 4 h and the 
reaction was stirred overnight. When the reaction was complete, the solvents were 
removed by rotary evaporation to give a crude product. Purification was performed by flash 
column chromatography on silica (3:1 acetate-hexane). Rf: 0.8 (100% EtOAc). Yield: 1.1 g, 
54.3%. ESI-MS: (C18H23N7O5, 417.1761) m/z = 418.1[M+H+], 435.2 [M+Na+].  
 
4-oxo-4-(((2R,3R,4S,5S,6R)-3,4,5-tris(2-cyanoethoxy)-6-((2-
cyanoethoxy)methyl)tetrahydro-2H-pyran-2-yl)amino)butanoate #4 
Cyanoethylated β-D-galatocopyranosyl azide #3 (1.1 g; 2.75 mmol) was dissolved in 20 
mL EtOAc, and reduced using an H-cube hydrogenator at 40°C; 30 bar and 2 mL/min. 
Completion of the reaction was determined by TLC (100% EtOAc). Succinic acid 
monobenzyl ester (59.8 mg; 2.87 mmol), HBTU (1.11 g; 2.96 mmol), and DIPEA (0.56 mL; 
3.2 mmol) were added to the reaction mixture and stirred at room temperature in an argon 
atmosphere for 16 h. The reaction mixture was then filtered through Celite and washed 
with MeOH. The solvent was evaporated and the residue dissolved in EtOAc (200 mL). 
The organic phase was washed with 5% aqueous HCl (3 × 100 mL), saturated aqueous 
NaHCO3 (2 × 100 mL), and saturated aqueous NaCl (50 mL), dried MgSO4, and 
evaporated. Pure product 4 (120.4 mg; 0.2 mmol; 7.5% yield) was obtained as colourless 
oil after flash chromatography on silica with EtOAc. ESI-MS: mass calculated: C29H35N5O8 
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(581.2) found: 582.8 [M+H+], 604.4 [M+Na+]. 1H NMR (500 MHz, CDCl3): 7.36-7.32 (m, 5H, 
Ar-H), 6.33 (d, 1H, CH), 5.13 - 5.07 (m, 3H, CH2OPh, NH), 4.22 - 4.19 (m, 1H, CH), 3.98 - 
3.53 (m, 12H, CH2O x 5, CH x 2), 3.48 – 3.44 (dd, 1H, CH), 2.70 – 2.49 (m, 12H, CH2 x 6).  
6-(2,3,4,6-Tetra-O-(butoxycarbonylaminopropyl)-β-D-galactopyranosylamino)-6-
oxobutanoic Acid #6  
Compound 4 (100 mg, 0.172 mmol) was dissolved in MeOH and cooled to 0°C on an ice 
bath. Cobalt chloride hexahydrate (335 mg; 1.4 mmol), and di-tert-butyl dicarbonate (200 
mg, 0.9 mmol) were added subsequently. Sodium borohydride (265 mg, 6.95 mmol) were 
added in portions over 30 min at 0°C and the mixture was stirred for 4 h at room 
temperature. The reaction was monitored by TLC (9:1 CHCl3/MeOH). After completion of 
Boc-protection, the mixture was filtered and evaporated under reduced pressure to give 
crude compound 5, which was then dissolved in MeOH. The benzyl protecting group was 
removed using H-cube hydrogenator at 40°C, 30 bar and 1mL/min. After completion of the 
reaction, the crude product was purified by flash chromatography on silica using the same 
eluent (9:1 CHCl3/MeOH) to give compound 6. Rf: 0.25 (9:1 CHCl3/MeOH). Yield: 21 mg, 
13.3%. 1-MS: mass calculated: C42H77N5O16 (907.5365) found: 808.8 [M-Boc], 908.8 
[M+H+], 931.0 [M+Na+]. 1H NMR (500 MHz, CDCl3): 5.33-4.83 (m, 6H, NH x 5, CH), 3.74 -
3.19 (m, 22H, CH2N x 4, CH2O x 5, CHO x 4), 2.81-2.39 (m, 4H, CH2O x 2), 1.73 (m, 8H, 
CH2 x 4), 1.38 (s, 36H, CH3 x 12).   
 
Synthesis of Peptides and Lipopeptides  
The synthesis of LHRH vaccines was performed using manual SPPS beginning with a lipid 
core peptide sequence, Gly-C16-C16-Gly-NH2. Boc chemistry was carried out in this 
synthesis. The coupling reactions were conducted in a reaction vessel. The first step was 
to prepare p-methylbenzhydrylamine (pMBHA) resin (0.45 mmol NH2/g; 0.02 mmol scale), 
mixed with HBTU/DIPEA. The pMBHA resin was swelled in anhydrous dimethylformamide 
(DMF) (10 mL/g of resin) for at least one hour. Subsequently, 10% (v/v) DIPEA/anhydrous 
DMF (10 mL/g of resin) was added to neutralise the hydrochloride salt 3 times at 15 
min/each time. The coupling procedures began when TFA was added twice, 1 min/each 
time to deprotect the Boc group from amino acids and then rinsed with DMF for at least 1 
min. For activation of the amino acids, 4.2 equiv was dissolved in 0.5 M HBTU/DMF 
solution (1.6 mL; 0.8 mmol; 4 equiv.) and DIPEA (212 µL; 1.22 mmol). Preactivated amino 
acid with HBTU and DIPEA were added to the resin for coupling to occur for 20-60 min.  
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Compound 6 was continuing coupled to the lipid core sequnce on pMBHA resin (0.25 
mmol NH2/g; 0.0115 mmol scale) using the same procedure as used for the coupling of 
amino acids. First, activation of compound 6 (1 min) was achieved by dissolving 
compound 6 (0.023 mmol; 2 equiv.) in 0.5 M HBTU/ DMF (0.04 mL; 0.023 mmol; 2 equiv.) 
followed by the addition of DIPEA (8 µL; 0.046 mmol). Then, the activated galactose core 
was added to the lipid core-conjugated pMBHA resin and coupled for 10 h. The galactose 
core that was coupled to the lipid core provided four peptide attachment points. For amino 
acids conjugated to a galactose core, 32.5 equiv of amino acids were activated by adding 
0.5 M HBTU/DMF (0.736 mL; 0.37 mmol; 32 equiv.) and DIPEA (80 µL; 0.46 mmol; 40 
equiv.). Following Boc-deprotection, four copies of the peptide antigen, pEHWSYGLRPG, 
were synthesised by stepwise SPPS mannually. After finishing the coupling of the whole 
sequence, the resin was thoroughly rinsed with DMF, DCM, and MeOH and dried in a 
desiccator before hydrogen fluoride (HF) cleavage. HF cleavage (10 mL HF/g resin) was 
performed at 0°C  for 2 h in the presence of 5% (v/v) p-cresol. Briefly, the HF was removed 
under reduced pressure, then ice-cold diethyl ether was added to precipitate the peptides. 
The mixture was filtered and the resultant compound was dissolved by addition of 40% 
acetonitrile (ACN)/H2O + 0.1% TFA. 
 
The crude peptide was purified using a preparative HPLC with a method 30-70% solvent B 
in 30 min, the final compound was obtained with a yield of: 200 µg, 3.3%; analytical HPLC: 
tR = 22.01 min; ESI-MS; [M + 2H]2+ m/z 2985.4 (calc 2985), [M + 3H]3+ m/z 1931.1 (calc 
1930.3), [M + 4H]4+ m/z 1448.6 (calc 1448), [M + 5H]5+ m/z 1159.5 (calc 1158.6), MW 
5788.62 g/mol. The data is shown in Figure 2.5 and Figure 2.6. 
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Figure 2.5. Characterisation of final product by ESI-MS. 
 
Figure 2.6. Characterisation of final product by analytical HPLC with 0-100% gradient of 
solvent B over 30 min. 
 
2.3 Results and discussion 
Succinic acid monobenzyl ester 
The yield of succinic acid monobenzyl ester synthesis was 60.7%. This linker was 
prepared through esterification of a succinic anhydride and benzyl alcohol with DMAP as a 
catalyst. This ester derivative possesses two carboxylic acid groups; one is protected by a 
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benzyl ring and the other one is a free carboxylic acid group that is able to form an amide 
bond with the azidated galactose derivative.   
 
Carbohydrates 
Through acetylation, bromination and azidation, the hydroxyl group at the anomeric 
position of the galactose molecule was substituted with an azido group to allow the 
attachment of succinic acid monobenzyl ester. The benzyl group of the ester was removed 
later via hydrogenation to give a free carboxylic acid group, providing a conjugating site for 
a lipopeptide. Furthermore, the other four-hydroxyl groups were modified to cyanoethyl 
groups, which were reduced to form amino groups by using sodium borohydrate and 
cobalt (II). Boc-protecting groups were attached to these amino groups by adding Boc 
anhydride. This Boc-protected carbohydrate building block was prepared to be used in Boc 
chemistry solid phase peptide synthesis. 
 
The synthesis of the Boc-protected galactose core was challenging during purification. 
When performing column flash chromatography, the Boc protecting group of compound 6 
tended to become cleaved in silica gel due to the low pH conditions. The polarity of the 
galactose derivative with one unprotected amine group was very close to the one, two, 
three or four unprotected amine groups, which caused difficulty during purification. In 
addition, the conversion efficiency of the chemical process in Boc protection for the 
compounds was very low. The whole synthesis started with 10 g of galactose and resulted 
in 20 mg of Boc protected galactose core.  
 
Peptide synthesis 
The final peptide derivative was successfully synthesised despite the low equivalence of 
Boc-protected galactose core used in the peptide synthesis. The final product was 
performed utilising a linear/step-wise strategy that resulted in a 3.3% yield after 
purification. Because of the very low yield in the synthesis of the galactose core 
compound, it was not taken further to animal testing for investigation of the compound’s 
immunogenicity.  
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2.4 Conclusion 
The anti-LHRH vaccine candidate with a galatose scaffold was successfully synthesised 
and characterised. However, the modification of galactose to a suitable galactose core 
was very inefficient. Intensive chemistry work is required to optimise the reaction 
conditions in order to yield sufficient compound for use in animal experiments. The 
multidisciplinary nature of the project allowed us to avoid this complicated optimisation by 
shifting the project’s focus from carbohydrate-based vaccine constructs to instead develop 
vaccine candidates with branched structures. This attempt has formed the basis of a future 
project that focused on the optimisation of carbohydrate scaffold synthesis for vaccine 
delivery [106]. The divergent approach for the synthesis of the carbohydrate building block 
used in this study was inefficient due to the need for multiple purification steps during the 
synthesis and also production of impurities caused by conjugation of multiple epitopes to 
the carbohydrate core. An alternative approach to overcome these problems is using a 
convergent synthetic method. Firstly, an alkyne-functionalised carbohydrate core would be 
synthesised. Four copies of LHRH epitope would be coupled to the core using azide-
alkene cycloaddition [107] . The synthesis and purification of two small building blocks 
(alkyne-functionalised carbohydrate core and LHRH epitope) would be easier than the 
divergent approach and is more likely to increase the yield of the final product.  
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Chapter 3: Synthesis, Characterization and biological evaluation of 
branched anti-LHRH vaccine candidates 
3.1 Introduction 
Vaccination against LHRH leads to anti-LHRH antibodies that neutralize LHRH and 
prevent the secretion of LH and FSH. This results in a reduced level of sex steroid and 
thus anti-LHRH vaccines can be used as in the treatment of hormone-dependent cancers 
[15, 108, 109] or as immunocontraceptives [109, 110] in both male and female models in 
animals. A large number of studies have targeted LHRH for anti-cancer therapy due to the 
high level of expression of LHRH receptors in a number of different malignant human 
tumours, including breast, ovary, endometrium, and prostate cancers [108, 111, 112]. In 
addition to the endocrine effect, the anti-cancer effect of LHRH conjugates is also a 
consequence of direct inhibition of tumour cell growth [113]. The direct growth-inhibitory 
effect of the LHRH constructs is considered a great advantage for their application to 
LHRH-receptor positive cancers. 
Although the LHRH peptide sequence (pEHWSYGLRPG) is a B cell epitope [114], it  does 
not trigger endogenous immune responses because it is a small self-antigen, and when 
administered along with an adjuvant LHRH does not elicit antibody response. Attempts in 
the 1970s to induce antibody production against LHRH by co-administering the peptide 
with CFA were unable to produce high antibody titres [40] because LHRH is only a B cell 
epitope Due to the small size of the peptide a T cell epitopes is also required to induce 
strong immune response [41, 42].  
 
In traditional vaccines, large inactivated toxins such as tetanus toxoid, diphtheria toxoid 
and diphtheria CRM197 were used as carriers to develop strong immune responses; 
whereas, in synthetic subunit vaccines, the carrier system can be a carbohydrate, a 
dendrimer structure such as poly lysine core, or lipid-based formulations such as 
liposome17, 18. Inclusion of large carrier proteins has been shown to induce suppression 
of the antibody response to a self hapten in the host and this is avoided in synthetic 
subunit vaccines.19, 20 Another advantage is that the problem with co-administration of 
toxic adjuvants is resolved by conjugating a self-adjuvanting moiety to the construct [115, 
116]. Selection of a suitable adjuvant, carrier system, molar ratio of carrier (e.g. lipid-based 
or protein carriers) to haptens (e.g. small peptides), and conjugation method are critical for 
developing an optimal vaccine against haptens [41, 42, 117].  
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Lipopeptides (LP) have been used successfully as immunogens in synthetic subunit 
vaccines to stimulate antibody and cellular responses [109, 118]. Novel candidates for 
vaccines against various pathogens, including GAS, have been developed by our group 
using branched polylysine core systems with the incorporation of lipoamino acids (LAAs) 
[119, 120]. This system is known as lipid core peptide (LCP) and mimics the actions of the 
bacterial adjuvants di- or tripalmitoyl-S-glyceryl cysteine (Pam2Cys and Pam3Cys, 
respectively) [78]. It has been demonstrated that LCP constructs mediate significant 
immunogenic effects without additional adjuvants [121, 122]. 
  
Pam2Cys and Pam3Cys were found to stimulate cytotoxic T lymphocytes as strongly as 
the wild type virus when conjugated with a T helper epitope from the influenza virus 
haemagglutinin, HA 2 [123]. Later, a LHRH construct that contained a T helper epitope 
branched with Pam2Cys and Pam3Cys induced potent immune responses in female 
BALB/c mice without an adjuvant. The most effective vaccine contained Pam2Cys 
conjugated through the ε-amine of a lysine placed in the middle of the vaccine sequence, 
and the LHRH epitope conjugated through its N-terminus [35]. In this study, we designed 
vaccine candidates using three components: a LP increases its hydrophilicity that 
contained two serines and two 2-amino-D,L-hexadecanoic acids (C16LAAs), a T helper 
epitope from the L chain of the influenza virus haemagglutinin, and LHRH [124, 125]. 
 
LHRH-based constructs bearing a LP system were synthesised as epitopes in different 
permutations. Each compound contained two serines and two 2-amino-D,L-hexadecanoic 
acids (C16LAAs) to serve as the self-adjuvanting moiety. This structure was a modified 
form of the LCP system, which has not been tested elsewhere with LHRH epitope. We 
also conjugated a T helper epitope from the L chain of the influenza virus hemagglutinin to 
boost the immune response [124]. We also report on their immunogenicity and ability to 
suppress folliculogenesis in mouse ovary, which is indicative of LHRH neutralization [100]. 
 
Here, in addition to investigating the potential immunogenicity of the constructs, as a 
preliminary study we examined their direct antiproliferative effect on a hormone-dependent 
LHRH-receptor positive cell line (LNCaP) and a hormone-resistant LHRH-receptor 
negative cell line (SKOV-3).  
 
Peripheral blood mononuclear cells (PBMCs) are a well-established model that is 
particularly relevant for testing of drug candidates on normal cells prior to clinical trials. 
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PBMCs were used to assess the potential cytotoxicity of the constructs against non-
cancerous mammalian cells compared to cancer cells. Drug-induced nonimmune 
haemolytic anaemia (i.e. damage to red blood cells) can lead to life-threatening conditions. 
Haemolysis assay was performed to test the potential of compounds to induce erythrocyte 
lysis in conditions where the compounds are in direct contact with blood, e.g. after 
intravenous administration. In vitro uptake studies were performed using murine 
splenocytes marked with CD11c and F4/80 antibodies to detect DCs and macrophages, 
respectively. 
 
In vivo experiments were performed to assess the ability of the synthesised constructs to 
induce an immune response. Information about the effect of LHRH analogues and 
vaccines on the morphology and function of the ovaries is limited [126]. Therefore, the 
effect of immunisation with anti-LHRH analogues on the follicular development and 
morphology of mouse ovaries was also investigated. 
 
3.2 Materials and methods 
General 
DMF, TFA, MeOH and DCM used in peptide synthesis were purchased from Merck 
Bioscience (Kilsyth, VIC, Australia). HATU and  Fmoc-amino acids were purchased from 
Mimotopes (Clayton, VIC, Australia), except for Fmoc-(ivDde])-OH which was purchased 
from ChemPep® (USA). Rink amide MBHA resin (100–200 mesh) with a substitution of 
0.79 mmol/g was purchased from Novabiochem (Melbourne, VIC, Australia). DIPEA used 
for activation of amino acids was sourced from Sigma Aldrich (Castle Hill, NSW, Australia). 
HPLC grade acetonitrile was obtained from Merck Bioscience (Kilsyth, VIC, Australia). Cell 
culture medium, PBS, and related reagents were purchased from Sigma Aldrich (Castle 
Hill, NSW, Australia) or Gibco Life Technologies (Mulgrave, VIC, Australia). Dde-C16 was 
synthesised according to a published protocol[127]. Streptavidin 1 mg, Tween-20TM and  
OPD were purchased from Sigma-Aldrich. Sterile 96-well plates (PS Immulon microtitre 
2HB F96) were obtained from Thermo Fisher (Scoresby, VIC, Australia). Skim milk powder 
was obtained from OXOID (England). PBS tablets were purchased from Fisher Scientific. 
Goat anti-Mouse IgG horseradish peroxidase (HRP)-conjugate was supplied by Bio-RAD 
(Regents Park, NSW, Australia). Haematoxylin was obtained from RCI Labscan 
(Bangtorad, Mueng Samutsakorn, Thailand) and eosin was purchased from Sigma Aldrich 
(Castle Hill, NSW, Australia). 
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Peptides were characterised by ESI-MS on a PE Sciex API3000 triple quadrupole mass 
spectrometer (Framingham, MA, USA) using a mixture of solvent A1 (0.1% AcOH in water) 
and B1 (0.1% AcOH in 9:1 acetonitrile/water) at 0.05 mL/min. 1H NMR spectra was 
recorded on a Bruker Avance 300 MHz spectrometer (Bruker Biospin, Germany) at 298 K 
in deuterated chloroform (CDCl3; Cambridge Isotope Laboratories, Andover, MA). 
Chemical shifts are reported in parts per million (ppm), with chemical shifts referenced to 
the residual CHCl3 peak (δ 7.24 ppm). NMR spectra were processed using Topspin 1.3 
(Bruker Biospin, Germany). A Varian Cary 50 Bio UV/vis spectrophotometer (US) (λ = 570 
nm) was used for absorbance measurements. RP-HPLC was performed on an Agilent 
1100 (US) system fitted with a binary pump, auto sampler, and a UV detector set to a 
wavelength of 214 nm. Preparative RP-HPLC was performed on a Shimadzu instrument 
(Kyoto, Japan; LC-20AT, SIL-10A, CBM-20A, SPD-20AV, FRC-10A) in linear gradient 
mode using 20 mL/min flow rate with detection at 230 nm.  Crude peptide purification was 
performed with solvent A2 (0.1% TFA in water) and solvent B2 (0.1% TFA in 9:1 
acetonitrile/water) on a Vydac preparative C4 column (214TP1022; 10 µm, 22 x 250 mm). 
Tissue sections were prepared using a manual Leica Rotary Microtome RM2245 
(Nussloch GmbH). Slides were scanned using a Scanscope (Aperio) Digital Slide Scanner. 
The images were analysed using Aperio Imagescope version 11.1.2.760 (RMIT, 
Melbourne, VIC, Australia). Fluorescence-activated cell sorting (FACS) analysis was 
performed using a LSR II flow cytometer (BD Biosciences). 
 
Synthesis of 2-((1-(4,4-Dimethyl-2,6-
dioxocyclohexylidene)ethyl)amino)hexadecanoic acid (Dde-C16-OH)  
5,5-dimethyl-1,3-cyclohexanedione (23 g, 0.16 mol) was dissolved in DCM (200 mL). 4- 
DMAP (29 g, 0.24 mol) and N,N’-dicyclohexyl carbodiimide (49.5 g, 0.24 mol) were then 
added and dissolved in the mixture by stirring. AcOH (14 mL, 0.24 mol) was added and the 
mixture was stirred for 16 h at room temperature. DCM was removed in vacuo by co-
evaporation of the crude product. After evaporation, EtOAc (300 mL) was added for 
extraction and the mixture was washed with 5% HCl (4 x 100 mL), brine (100 mL) and 
dried with MgSO4. The solvent was evaporated to produce oil, which was purified by flash 
chromatography (Hex:EtOAc, 3:2). The fractions containing the final product were 
evaporated in vacuo to afford an orange oil, which was cooled to yield pale yellow crystals 
(2-acetyldimedone, Dde-OH) in 61% yield (17.89 g): Rf (Hex:EtOAc, 3:2) = 0.76; 1H 
Nuclear Magnetic Reasonance (NMR) (CDCl3, 300 MHz): δ = 2.59 (3H, s, CH3); 2.52 (2H, 
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s, CH2), 2.35 (2H, s, CH2); 1.06 (6H,  s, C(CH3)2). Chemical structure (Figure A4) is 
attached in Appendix A. 
 
The 2-amino-D,L-hexadecanoic acid hydrochloride was synthesised using a published 
method [128]. The resulting 2-Amino-D,L-hexadecanoic acid hydrochloride (6.3 g, 23.5 
mmol) and Dde-OH (4.3 g, 23.5 mmol) were suspended in ethanol (75 mL) then 
Triethylamine (TEA; 8 mL) was added and the mixture was refluxed for 2 days at 80˚C. 
After evaporating the solvent, the crude product was dissolved in EtOAc (400 mL) and 
washed with 5% HCl (3 x 100 mL), then dried over MgSO4. The extracted crude 
compounds were evaporated and crystallised with cold acetonitrile to produce the pure 
product as a white solid of 40% yield (4 g): Rf (CHCl3:MeOH:AcOH, 9:0.8:0.2) = 0.4; ESI-
MS (C26H45NO4, 435.3): m/z = 436.4 [M+H]+ (calcd. 436.3); 1H NMR: δ = 4.38 (1H, dd, α-
CH), 2.52 (3H, s, C(NH)CH3), 2.40 (4H, s, 2CH2CO), 2.04-1.90 (2H, m, β-CH2), 1.46-1.23 
(24H, m, 12CH2), 1.02 (6H, s, C(CH3)2), 0.86 (3H, t, CH3). 
 
Peptide synthesis  
Fmoc chemistry was used to synthesise all vaccine candidates and the control peptide. 
Briefly, for the synthesis of compounds 1 [Th(K-LP)LHRH] and 2 [LHRH(K-LP)Th], the full 
peptide sequence was assembled first, with Lys-ivDde-OH separating the T helper and 
LHRH. The N-terminus of T helper epitope was attached to an acetyl group in using 
DMF/acetic anhydride/DIPEA (9:0.5:0.5) to protect its free amino group. The presence of a 
pyroglutamate moiety at the N-terminus of LHRH prevented further coupling, thus 
acetylation of this end is unnecessary. The ivDde-protecting group on the lysine was 
removed by treatment with 2% hydrazine hydrate and coupled with 2 copies of Fmoc-Ser-
OH and 2 copies of Dde-C16-OH. For the synthesis of compounds 3 [LHRH(K-Th)LP] and 
4 [Th(K-LHRH)LP], the lipid moiety was coupled to the resin before the Fmoc-Lys-ivDde 
was attached. The peptide sequence on the α-amine of lysine was completed first, 
followed by the peptide sequence on the ε-amine. Compound 5 [Th(K)LP] was synthesised 
via step-wise synthesis strategy by sequential coupling of lipopeptide, lysine and the T 
helper epitope with an acetyl group at the N-terminus. Finally, the peptides were cleaved 
from the resin with standard cleavage conditions (95% trifluoroacetic acid (TFA)/2.5% 
triisopropylsilane (TIS)/2.5% distilled H2O). The solvent was removed under a stream of 
nitrogen. The crude peptides were precipitated by addition of cold diethyl ether, dissolved 
in acetonitrile/water/TFA (50:50:0.1), and lyophilized. 
 
 33 
Purification  
The crude peptides were purified by preparative RP-HPLC using a Grace Vydac C4 
column (10 µm, 22 x 250 mm) with solvent A2 and solvent B2. Two methods were applied: 
Method 1 (for compounds 1 and 2): a gradient of 30% to 60% solvent B2 over 40 min, 20 
mL/min; and Method 2 (for compounds 3 and 4): 30% to 80% solvent B2, 40 min, 20 
mL/min. The fractions collected from preparative RP-HPLC were checked by ESI-MS for 
presence of the product. The purity was examined by analytical RP-HPLC using two 
different methods on a Grace Vydac C4 column (5 µm, 4.6 x 250 mm) and a gradient of 0 
to 100% B2 over 30 min at 1 mL/min. Pure fractions were lyophilized to obtain the product. 
Compound 1. Yield: 15%; HPLC: Rt = 19.3 min (method 1); ESI-MS: [M + 3H]3+ m/z 
1270.9 (calc 1269.3), [M + 4H]4+ m/z 953.3 (calc 952.2), [M + 5H]5+ m/z 762.9 (calc 762), 
[M + 6H]6+ m/z 636.5 (calc 635.1); MW 3807.51 g/mol. 
 
Compound 2. Yield: 16%; HPLC: Rt = 19.3 min (method 1); ESI-MS: [M + 3H]3+ m/z 
1250.6 (calc 1249.7), [M + 4H]4+ m/z 938.0, 938.8 (calc 937.5), [M + 5H]5+ m/z 750.7 (calc 
750.2), [M + 6H]6+ m/z 626 (calc 625.3); MW 3747.48 g/mol. 
 
Compound 3. Yield: 14%; HPLC: Rt = 19.7 min (method 1); ESI-MS: [M + 3H]3+ m/z 
1264.2 (calc 1262.7), [M + 4H]4+ m/z 948.8 (calc 947.2), [M + 5H]5+ m/z 759.5 (calc 758); 
MW 3787.5 g/mol. 
 
Compound 4. Yield: 12%; HPLC: Rt = 20.2 min (method 1); ESI-MS: [M + 3H]3+ m/z 
1264.5 (calc 1262.7), [M + 4H]4+ m/z 949.1 (calc 947.2), [M + 5H]5+ m/z 759.6 (calc 758); 
MW 3787.5 g/mol. 
 
Compound 5. Yield: 5%; HPLC: Rt = 21.1, 22.3 min (method 1); ESI-MS: [M + 3H]3+ m/z 
876 (calc 875.75 ), [M + 4H]4+ m/z 657 (calc 657); MW 2624.26 g/mol. 
 
 
Dynamic light scattering (DLS)  
Particle size measurement was performed using a Malvern NanoSeries zetasizer and 
software from Malvern Instruments Ltd. The compounds were dissolved in 10% Dimethyl 
sulfoxide (DMSO) at 100 nM and 10 µM. Particle sizes were evaluated at 25˚C in 
disposable cuvettes using a non-invasive backscatter system and scattering angle of 173˚.  
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Transmission electron microscopy. 
A JEM-1010 (JEOL Ltd., Japan) transmission electron microscopy (TEM) was used in this 
study, operating at 100 kV. The samples were prepared on carbon coated 200 mesh grids 
for 2 min. Excess liquid was wicked away using filter paper. Microimages were taken to 
analyse particle size and shape using AnalySIS® software (Soft imaging Systems, 
Megaview III, Munster, Germany).  
 
Cell culture  
The LNCaP human prostate adenocarcinoma cell line was kindly provided by Professor 
Judith Clements from the Queensland University of Technology, Translational Research 
Institute. LNCaP cells were maintained in T-75 flasks (Nunc, Australia) with RPMI-1640 
media supplemented with 5% foetal bovine serum (FBS), 1% L-glutamine, and incubated 
in 95% humidity and an atmosphere of 5% CO2 at 37°C. SKOV-3, the Sloan-Kettering 
HER2 3+ ovarian cancer cell line were kindly donated by Professor Rodney Minchin, 
School of Biomedical Sciences, The University of Queensland. They were grown in 
Dulbecco's Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 1% 
glutamine, and 1000 U/mL streptomycin/penicillin. The culture medium was changed every 
second day for both cell lines. Cells were subcultured using 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) when they had reached 80% confluence. 
 
In vitro haemolysis assay  
The use of human blood from a healthy volunteer was undertaken with approval from The 
University of Queensland Ethics Committee (Ethics Approval Number: 2009000661). Four 
LHRH vaccine candidates were solubilised in 10% DMSO in PBS. Compound solutions 
(100 µL) were then added to 100 µL of blood in each well of a 96-well plate in triplicate at 
different concentrations (10, 50 and 100 µM). The vehicle (10% DMSO in PBS) and 
sodium dodecyl sulfate (SDS) were used as negative and positive controls, respectively. 
After 1 h incubation at 37°C, the plate was centrifuged to pellet the red blood cells. The 
supernatant (75 µL) was transferred to a new flat-bottomed 96-well plate and the 
haemoglobin concentration was measured at an absorbance of 540 nm. The percentage 
of red blood cell disruption was quantified relative to positive control samples lysed with 
the detergent SDS.  
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Isolation of peripheral blood mononuclear cells (PBMCs)  
PBMC isolation was achieved by Ficoll gradient centrifugation of whole blood taken from 
healthy volunteers (Ethics Approval Number: 2009000661). Briefly, 4 mL of blood was 
diluted with the same volume of cell culture medium and layered on top of Ficoll density 
gradient medium. The tube was centrifuged at 400 g for 30 min. without disturbing the 
erythrocyte/granulocyte pellet, the mononuclear cell layer was removed from the plasma-
Ficoll interface. Mononuclear cells were washed three times with RPMI 1640 and then 
resuspended at a concentration of 1 × 106 cells/mL in RPMI 1640 with 10% heat 
inactivated FBS. Cells were activated with 10 µg/mL of phytohaemagglutinin (PHA) and 
cultured in a 96-well microplate for 48 h at 37°C in a CO2 incubator. 
 
In vitro antiproliferative activity  
The effect of compounds on cell proliferation was investigated using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on PBMCs, and 
prostate (LNCaP) and ovarian (SKOV-3) adenocarcinoma cell lines. For the cell viability 
assay, 2 x 104 LNCaP cells, 1 x 104 SKOV-3 cells or 1 x 105 PBMCs (in 90 µL) were 
seeded into the respective wells of a 96-well microplate and 10 µL of the vaccine 
constructs 1-4 were added at 2.5, 5, 10 and 25 µM in 10% DMSO/PBS. PHA (10 µL) was 
added to the wells that contained PBMCs to activate cell growth. After 48 h incubation 
(37°C, 95% humidity, 5% CO2), 10 µL MTT (5 mg/mL) was added to each well and 
incubated for 4 h, then 100 µL of acidified isopropanol (0.1 N HCl) was added to dissolve 
the formazan crystals. The absorbance was measured by an UV/vis spectrophotometer at 
a wavelength of 570 nm. Cell viability was expressed as a proportion of the mean viability 
of the cells treated with the negative control (10% DMSO in PBS) ± standard error mean 
(SEM). A saturated SDS solution was used as the positive control.  
 
Animals  
Female BALB/c mice were purchased from The University of Queensland biological 
resources breeding facility and housed in groups of four per cage for a minimum 5-day 
acclimatisation period. Mice were housed in an artificially lit room on a 12 h light/12 h dark 
cycle at controlled temperature (22.2 ± 0.2°C; mean ± SEM) and humidity (51–65%) with 
food and water available ad libitum. The animal experimentation protocols were approved 
by The University of Queensland Animal Ethics Committee (AEC#SCMB/005/11/ARC) and 
performed according to NHMRC animal handling guidelines. 
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Immunisation study  
Six groups of 8 female BALB/c mice were treated with a primary intramuscular (i.m.) 
injection of immunogen at a dose of 50 µg/mouse in 50 µL (262-266 µM) on day one. Mice 
were administered two boosters (same as the primary dose) at days 28 and 56. The 
samples were prepared in 10% DMSO in PBS. An emulsion of compound 1 was prepared 
in 1:1 CFA : PBS as the positive control, followed by 50 µL boosters with PBS. Sterile PBS 
was used as a negative control. Mice received boosters at days 28 and 56 after the 
primary injection. Blood samples (10 µL per mouse) were collected by tail snip on the day 
prior to each injection and 9 days after the second booster (days 27, 55, and 65). The 
blood was diluted 1:10 in PBS and allowed to clot at room temperature for ~30 min then 
centrifuged at 650 g for 10 min to pellet the red blood cells. Serum was stored at -20°C. 
Anti-LHRH antibody titres were determined by enzyme-linked immunoabsorbent assay 
(ELISA). 
 
Enzyme-linked immunosorbent assay (ELISA)  
96-well plates were coated with streptavidin (100 µL, 5 µg/mL, incubated to dryness at 
37°C overnight), blocked with 150 µL of 5% skim milk in 0.05% Tween/PBS (4°C 
overnight), then washed 3 times with 0.05% Tween-20/PBS. LHRH-K-Biotin (kindly 
synthesised by Dr. Daryn Goodwin [85], 100 µL/well, 5 µg/mL in 0.05% Tween-20/PBS) 
was added to the plates and the plates incubated at 37°C for 90 min then washed three 
times. Serial 2-fold dilutions of murine sera were prepared in 0.5% skim milk/PBS by 
adding serum to each well at a starting dilution of 1:100 (final well volume of 100 µL). The 
plates were incubated at 37°C with 95% humidity for 1.5 h then washed 6 times with 
distilled water and 3 times with 0.05% Tween-20/PBS. Horseradish peroxidase-conjugated 
goat anti-mouse immunoglobulin (diluted 1:3000 in 0.5% skim milk/PBS) was added to the 
plates and the plates incubated for 1 h at 37°C. The plates were washed 6 times with 
distilled water and 5 times with 0.05% Tween-20/PBS. Peroxidase substrate (OPD) 
solution (100 µL/well) was added to the plates and incubated in darkness for 30 min. The 
absorbance of the solutions was measured at 450 nm using a microplate reader. A mean 
of absorption for PBS antisera plus 3 times its standard deviation was used as a cut-off 
value to determine the effective antibody titre. 
 
Histological evaluation  
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The ovaries from vaccinated and control mice were collected immediately after euthanasia 
on day 65 and fixed in 10% buffered neutral formalin. Tissue was dehydrated through a 
series of graded ethanol baths to displace the water, and then infiltrated with wax. The 
infiltrated ovaries were embedded into paraffin wax blocks and thin sectioned into 6 µm 
slices using a manual Leica Microtome. Sections were stained with haematoxylin and 
eosin (H&E stain) and then mounted. Mounted slides were scanned by a Scanscope 
(Aperio) Digital Slide Scanner. The ovaries were examined and antral and atretic follicles 
and corpora lutea were further examined and classified based on their morphological 
features [129]. Follicles were classified as healthy (early antral and antral or Graafian) if 
they contained an intact oocyte, organised granulosa cell layers and follicular space 
(antrum, a fluid-filled cavity adjacent to the oocyte). Follicular atresia was characterised by 
deformed shape, vacuolation and/or fragmentation of the oocyte [130]. The antral and 
atretic ratios were determined as a percentage of the total follicle count.  
 
Splenocyte isolation, processing and uptake assay  
A single cell suspension of mice spleens was prepared by passing the tissue through 
stainless steel mesh. Erythrocyte contamination was removed by washing with red cell 
lysis buffer (Sigma). The remaining cell population was seeded at a density of 4 × 104 
cells/well in a 96-well flat-bottom plate in phenol free IMDM Glutamax medium (Gibco®, 
Life Technologies). The media was supplemented with 10% FBS, 50 µM 2-
mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin. DCs were marked 
with CD11c-A660 and macrophages with F4/80-APC-Cy7 antibodies. The compounds 
were labelled by adding 0.5 µL of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate (Dil; Vybrant®, Life Technologies) to 100 µL of compound (50 µM) in PBS and 
incubated at 4ºC for 30 min. Cells were incubated with Dil-labelled compounds overnight. 
Cells were removed from the plate and transferred to a 96-well V-bottom plate. The plate 
was centrifuged at 400 g for 5 min and supernatants discarded. Cells were resuspended in 
50 µL Fc receptor block (eBioscience) and incubated at 4°C for 10 min, centrifuged at 400 
g for 5 min then resuspended in FACS buffer (PBS, 0.02% sodium azide, 0.5% BSA) that 
contained CD11c-A660 (eBioscience) and F4/80-APC-Cy7 (BioLegend, Pacific Heights 
Blvd, San Diego, CA, USA) antibodies and incubated at 4°C for 30 min. The cells were 
washed three times with FACS buffer and centrifuged as above. Cells were then 
resuspended in 50 µL of fixation buffer (eBioscience) and incubated for 20 min at room 
temperature. After fixation the cells were washed (150 µL) then resuspended in 300 µL of 
FACS buffer and analysed by BD LSR II flow cytometer. The fluorescent intensities of 
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PBS-treated or dextran-FITC treated cells were also measured as negative and positive 
controls, respectively. Uptake was calculated as the percentage of cells that were double 
positive for Dil (compound) and CD11c-A660 or F4/80-APC-Cy7. 
 
Data analysis 
The percentage of haemolysis was calculated using the following equation. A540 is the 
mean absorbance of a treatment group, max A540 is the mean absorbance of the positive 
control, and min A540 is the mean absorbance of the negative group. %  𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =    !!"#!!"#!!"#!"#$!"#!!"#$!"# × 100 
 
Cell viability was calculated as the percentage of average absorbance of the test 
supernatant divided by the average absorbance of the negative control. %  𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦   =    !"#$  !"  (!"#$%&)!"#$  !"  (!"#$%&'"  !"#$%"&) × 100 
 
All data were expressed as mean (± SEM). One-way analysis of variance (ANOVA) and 
Dunnett’s post hoc test were performed using GraphPad PrismTM (V6.0) software to 
determine statistical significance of the data (p < 0.05).   
 
3.3 Result and discussion 
Design and synthesis  
Four lipopeptide-based vaccine candidates were designed using four different 
components: a lipopeptide comprised of two copies of C16LAA and two copies of serine; a 
T helper epitope from the L chain of the influenza virus haemagglutinin; the B cell epitope, 
LHRH (Figure 3.1 and 3.2); and a central lysine to permit the synthesis of branched 
structures. Compounds 2, 3 and 4, were designed using a LHRH epitope with a free amino 
group at its N-terminus while the LHRH epitope in compound 1 was attached to the lysine 
through its N-terminus with a free amino group at the C-terminus. All compounds were 
synthesised via solid phase peptide synthesis using the Fmoc in situ neutralisation 
protocol and purified to a single peak (> 95% purity) by RP-HPLC and characterised using 
ESI-MS.  
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Figure 3.1. Schematic structures of anti-LHRH vaccine candidates. Each vaccine 
candidate incorporates an influenza helper T cell epitope (GALNNRFQIKGVELKS), a 
LHRH epitope (pEHWSYGLRPG) and two copies of C16 LAA. Ac = acetyl group, LP 
= Lipopeptide, Th = T helper epitope.  
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Figure 3.2. Chemical structure of the four anti-LHRH vaccine candidates. 
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Dynamic light scattering and Transmission electron microscopy 
Amphiphilic peptides often have a tendency to self-assemble into nano or microparticles in 
solution [131]. The compounds presented here possess hydrophilic (LHRH and influenza 
haemaglutinin HA2) and hydrophobic (lipid core) properties, thus they were expected to 
form particles in solution. 
The measurement of particle size was conducted under condition of 10%DMSO/PBS 
solution, room temperature and immediate measurement after dissolving. The results of 
the DLS measurement showed a wide distribution of particle sizes of the four compounds, 
resulting in a high polydispersity index (PDI). All compounds tended to form large 
nanoparticles and microparticles with sizes typically above 300 nm (Table 3.1).  
Table 3.1. Particle size analysis of compounds 1-4 by DLS. 
Method	   	  
1	  
Size	  (nm)	  
2	  
	  
3	  
	  
4	  
DLS	   >300	   >300	   >300	   =300	  
 
 
Particle size was measured and topology observed by TEM (Figure 3.3) with a 500 nm 
bar. Only some results are presented in this study due to the variable sizes obtained 
through images. Compound 1 revealed a size range from 40-135 nm in this image. 
However, a particle size above 300 nm was also observed. Compound 2 had a size range 
from 10-2500 nm. Compound 3 had a size range from 15-180 nm, 465-2500 nm and 
compound 4 had particle sizes ranging from 10-50 nm. A particle over 300 nm was also 
observed. No direct correlation was observed between the results of DLS and TEM due to 
compounds not forming specific range of particle size and varable topological results in 
TEM images. Here, correlation between particle size with uptake by APCs and 
immunogenicity remains unclear. Four branched anti-LHRH vaccine structures were more 
likely to form unified shaped and size variable aggregates. We assume that small particles 
observed in all images resulted in the high percentage uptake by DCs and macrophages 
as well as potent immunity. It has been reported that nanobeads of 40–50 nm were better 
uptaken by DCs than larger particles and they induced the strongest immune response 
[132]. Moreover, a study has shown that self-assembled peptide nanoparticles of 25 nm in 
size induced a high level of IgG response in immunised mice against Malaria [133].  
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Figure 3.3. Image of four branched compounds observed by transmission electron 
microscopy, 1 (A), 2 (B), 3 (C) and 4 (D) at 500 nm scale. Particle size observed from 
each compound was as follows: compound 1 (40-135 nm), compound 2 (>200 nm), 
compound 3 (15-2500 nm), and compound 4 (10-50 nm). 
Table 3.2.  Particle size analysis of compounds 1-4 by TEM. 
Method	   	  
1	  
Size	  (nm)	  
2	  
	  
3	  
	  
4	  
TEM	   40-­‐135	   >200	   15-­‐2500	   10-­‐50	  
 
In vitro haemolysis assay  
Attaching lipids to the vaccine construct is a useful method of creating self-adjuvanting 
vaccine candidates. However, the hydrophobic moiety of an amphipathic molecule can 
disrupt cell membranes [134]. The in vitro haemolysis assay was performed to test 
C 
A B 
D 
500 nm 500 nm 
500 nm 500 nm 
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whether any of the compounds 1-4 can induce any damage to RBCs, which can result in 
haemoglobin release into the plasma (as an indicator of red blood cell lysis). Four  
compounds were compared to the negative control goup (Figure 3.4). Compound 1 did not 
produce a significant haemolytic effect at three concentrations (10, 50 and 100 µM, Figure 
3.4), when compared to the negative control group (10% DMSO in PBS, p > 0.05). No 
significant haemolysis was detected for any of the compounds at a concentration of 10 µM 
with no signs of haemolysis in the animals after intramuscular administration of the 
constructs. However, the in vitro haemolysis assay suggests that intravenous 
administration of these compounds or possibly those compounds with similar structure 
should proceed with caution if there is a need for that. At higher concentrations red blood 
cells were lysed up to 18% by 50 µM of compound 2 and up to 28% after treatment with 
100 µM of compound 4 (p < 0.05).  
 
Figure 3.4. The haemolytic effect of the four anti-LHRH vaccine candidates, 1, 2, 3 
and 4, on human erythrocytes examined at different concentrations, 10, 50 and 100 
µM, with 10% DMSO. The treatments were performed in triplicate. Sodium dodecyl 
sulfate (SDS) was used as a positive control and 10% DMSO in PBS was used as a 
negative control (*, p < 0.05). The statistic significance shown was compared to the 
negative control. 
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In vitro antiproliferative activity  
A significant reduction in cell viability, up to 55%, was observed following treatment of 
LNCaP cells with 25 µM of any of the compounds (Figure 3.5a). Compounds 2 and 3 
significantly inhibited the growth of these cells at 5 and 10 µM (Figure 2.4a, p < 0.05) in 
contrast to the native LHRH, which did not produce any significant effect on the 
proliferation of LNCaP cells (p > 0.05).  
The compounds were screened for cytotoxicity using a MTT assay, in which NADPH-
dependent living cells convert MTT to purple formazan [135]. This test was performed on 
hormone-sensitive LHRH receptor-positive LNCaP cells and hormone resistant-LHRH 
receptor-negative SKOV-3 cells to investigate whether the constructs can directly inhibit 
tumour growth, which would provide an extra benefit in addition to their primary effect as 
potential vaccines against hormone-dependent cancers. In addition, the compounds were 
also examined on normal PBMCs to investigate direct antiproliferative effect.  Binding 
between LHRH constructs and LHRH receptors has been shown to inhibit the mitogenic 
signal transduction pathway of the epidermal growth factor (EGF) receptor in prostate, 
endometrial, ovarian, and breast cancer cell lines,[136] resulting in an antiproliferative 
effect on LHRH receptor positive cells. Furthermore, based on results of the 
antiproliferative assay, those compounds showed active can be further modified as LHRH 
agonists. The significant growth inhibitory effect of LHRH vaccine constructs at all 
concentrations in LHRH receptor-positive LNCaP cells was observed. Other than that, the 
examination on SKOV-3 showed Compounds 3 and 4 inhibited the growth of SKOV-3 cells 
by approximately 25% at the highest concentration (25 µM, p < 0.05). No significant effect 
was observed on these cells following treatment by peptide constructs 1 and 2 at either 
concentrations or 3 and 4 at the lower concentration (Figure 3.5b, p > 0.05). The 
constructs were not tested at concentrations lower than 10 µM due to inhibition resulting in 
poor growth. These results indicated the antiproliferative effect was weaker in the LHRH 
receptor-negative SKOV-3 cell line. None of the vaccine candidates had an inhibitory 
effect on the growth of PBMCs at either concentration (10 and 25 µM) when compared to 
the negative control (p > 0.05). On the contrary, LHRH and the vaccine candidates 
stimulated the growth of these cells. PBMC counts increased by up to 30% when treated 
with compound 2 at 10 µM (Figure 3.6). These results are consistent with previous studies 
that found that LHRH constructs promoted lymphocyte proliferation [137] and produced 
LHRH receptor-mediated immunomodulatory effects [138].  
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Figure 3.5. Antiproliferative effect of anti-LHRH peptide vaccine candidates on a) 
LNCaP prostate cancer cells at four different concentrations (2.5, 5, 10 and 25 µM), 
and b) SKOV-3 ovarian cancer cells at two different concentrations (10 and 25 µM) 
using MTT assays. Data presented are means (± SEM) from separate experiments 
performed in triplicate (*, p < 0.05; **, p < 0.01; ***, p < 0.001).   
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Figure 3.6. Antiproliferative effect of anti-LHRH peptide vaccine candidates on 
peripheral blood mononuclear cells (PBMCs) at two different concentrations (10 µM 
and 25 µM). Data presented are means (± SEM) from separate experiments 
performed in triplicate (***, p < 0.001). 
 
Uptake of compound by dendritic cells and macrophages  
The uptake of the compounds by DCs and macrophages was measured by incubating the 
Dil-labelled compounds with splenocytes marked with CD11c-A600 and F4/80-APC-Cy7 
antibodies. The resulting cell-associated fluorescence was measured by flow cytometer. 
The results show that the four compounds were efficiently taken up by DCs (Figures 3.7a, 
b). In addition, of the four compounds, the uptake of compound 1 was significantly higher 
than compounds 3 and 4. No significant difference in uptake was found among groups 
treated with compound 2, 3 or 4. Similar trends were observed in uptake by macrophages 
but there was no significant difference between the compounds. These data indicate that 
antigen uptake may lead to APC activation, however, no correlation was found between 
dendritic and macrophage cell uptake and the level of antibody titres in this study.  
 
 47 
 
Figure 3.7. Uptake of compounds by, a) dendritic cells, and b) macrophages. Four 
anti-LHRH peptide vaccine candidates (50 µM) were incubated with antigen 
presenting cells (DCs and macrophages) overnight at 37°C. PBS and Dextran were 
negative and positive controls, respectively. The statistic signifcances are from 
comparison to the negative control. Data presented are means (± SEM) from 
separate experiments performed in triplicate (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
  
Immunogenicity studies   
The anti-LHRH vaccine candidates were administrated intramuscularly to female mice on 
days 0, 28 and 56 of the experiment to investigate the systemic LHRH-specific immune 
response. The positive control group was administered compound 1 with CFA, while the 
negative control group was administered sterile PBS. The antibody titres of the samples 
collected on day 27 did not show a significant difference among the four treatment groups, 
or positive and negative controls (Figure 3.8a, p > 0.05). The anti-LHRH antibody titres in 
mice treated with constructs 2 and 3 showed a significant increase at day 55 (before the 
third dose) compared to the negative control group (Figure 3.8b, p < 0.01). The antibody 
titres increased dramatically 9 days after the third vaccination (day 65; p < 0.01) in all four 
test groups and the positive control group (Figure 3.9). In addition, constructs 2, 3 and 4 
induced significantly higher antibody titres than construct 1 (p < 0.001) and compound 3 
produced significantly higher antibody titres than the positive control (p < 0.05). In order to 
investigate the selectivity of the produced antibodies to LHRH, compound 5 was 
synthesised containing the T helper epitope and lipid moiety but without the LHRH epitope. 
The mouse antisera raised against compound 3 showed no significant binding affinity to 
compound 5 (Figure 3.10, p > 0.05). 
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All four vaccine candidates induced significant anti-LHRH antibody titres after three 
intramuscular injections. Lipidated LHRH peptides have previously been shown to elicit a 
significant antibody response in murine models [139]. Zeng et al. investigated a series of 
LHRH-based vaccine constructs where the LHRH epitope was coupled to the C-terminus 
of each compound but the position of T helper and lipid moiety (Pam2Cys) was varied. 
The construct that bore the lipid moiety on the ε-amine of the core lysine was the most 
immunogenic [140]. We previously investigated the immunogenicity of similar constructs 
and found that LHRH with an added lipopeptide was unable to induce an immune 
response without the inclusion of a T helper epitope [85]. This discovery led to the 
development of compound 1, which contained three essential components (LHRH epitope, 
T helper epitope, lipid moiety) to improve the immunogenicity of the anti-LHRH vaccine 
constructs. In compound 1 the T helper was at the N-terminus, LHRH at the C-terminus 
and the lipid moiety on the ε-amine of a lysine in the middle of the sequence between the 
two epitopes (Figure 3.1). This structure successfully induced significant production of anti-
LHRH antibodies in BALB/c mice when co-administered with CFA [85]. 
 
Constructs 2, 3 and 4 were designed to investigate the effect of altering the arrangement 
of the components from compound 1. In construct 2, the LHRH epitope was attached to 
the α-amine of a central lysine, which was used as a linker between LHRH and the T 
helper epitope, while the lipid moiety was attached to the ε-amine of the central lysine. 
Interestingly, the second generation constructs, candidates 2, 3 and 4, induced higher 
antibody titres than compound 1 or the positive control, compound 1 + CFA. Candidates 2, 
3, and 4 differed from compound 1 and similar vaccine candidates in previous studies 
[125], because the LHRH epitope was conjugated through its C-terminus, leaving the N-
terminus available for intermolecular interactions. Despite having the three key 
components in different positions, no significant difference was observed between the 
immunogenicity of compounds 2, 3 and 4.  
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Figure 3.8. Anti-LHRH-specific antibody titres (log10) at (a) the first bleed on day 27, 
(b) the second bleed on day 55. 
 
 
 
Figure 3.9. Anti-LHRH-specific antibody titres (log10) at the final bleed on day 65 after 
primary immunisation of each individual mouse. Mean anti-LHRH-specific antibody 
titres are represented as a bar. Statistical analysis was performed using a one-way 
ANOVA followed by Tukey’s post hoc test (***, p < 0.001).  
 50 
 
Figure 3.10. Binding affinity of the antisera raised against compound 3 (from two 
different blood collections) to compound 5 (Th-LP). Statistical analysis was 
performed using a one-way ANOVA followed by the Tukey post hoc test (* p > 0.05). 
 
Effect of anti-LHRH conjugates on ovarian histology and folliculogenesis  
Successful production of anti-LHRH antibodies disturbs hypothalamic–pituitary–gonadal 
axis by decreasing the level of circulating LHRH. This results in an overall suppression of 
pituitary gonadotropins (FSH and LH) following immunization and causes different 
physiological and morphological changes such as suppression of oestrus cycle, 
folliculogenesis, and morphology changes in the sex organs [100]. Histology studies were 
performed to investigate the effect of in vivo treatment with anti-LHRH vaccine candidates 
on ovarian morphology of mice. The method has been described previously in this chapter. 
The histology slides were examined for changes caused by the immunisation. The ovaries 
of the PBS control mice showed healthy and large corpora lutea with many early and 
mature antral follicles (Figure 3.11A). Antral follicles found in the control ovaries had an 
ordered cumulus granulosa cell layer and defined areas between the granulosa cells and 
the ovum, and between the granulosa and the stroma (Figure 3.11B). The ovaries of mice 
treated with anti-LHRH vaccine candidates and the positive control group had reduced 
follicular development and marked degenerative changes (Figures 3.11C-G). Vaccination 
with the test compounds was associated with a decrease in the number of healthy antral 
follicles and an increase in the number of degenerative antral and atretic follicles (Table 
3.2). The ratio of atretic to antral follicles was approximately 30% higher in treated ovaries 
than in the negative control group. A marginal increase in the number of corpora lutea in 
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treated mice compared to PBS control mice was also observed (Table 3.2.). In most of the 
treated ovaries the granulosa cells had lost their typical arrangement and showed a 
random scattered pattern with poor alignment around the ovum. Degeneration of ova in 
most of the follicles of the treated ovaries was the principal observation in histological 
studies of all treatment groups as well as the positive control group. In these groups the 
majority of follicles were shrunken and contained a deformed ovum with folded cell walls, 
absent nuclei and, in some cases, cloudy degeneration (Figures 3.11.C, E and F). The 
inhibition of folliculogenesis (as graded by histopathology scores) correlated with a 
significant increase in anti-LHRH antibody titres after treatment with the four vaccine 
candidates. This effect was observed when other LHRH vaccines or analogues were 
tested and was found to result from the suppression of LHRH secretion or the 
neutralisation of LHRH by anti-LHRH antibodies and the blockage of LHRH action on 
gonadotrope cells, reducing the expression of oestrogen receptors and circulating 
oestradiol [20, 141]. Gonadotropin stimulation is required for proliferation and 
differentiation in late antral follicles [95, 96]. The inhibition of LHRH is consistent with the 
increase in atretic follicles that was observed in the vaccinated mice. These observed 
morphological changes in the ovaries, together with the insignificant binding affinity of the 
antisera from immunised mice against compound 3 with compound 5, suggested that the 
produced antibodies were functional and selective to LHRH peptide. 
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Figure 3.11. (A) Ovary of a mouse from the PBS control group showing normal corpus 
luteum, healthy early antral follicles (An) and a few atretic follicles (At). (B) A mature 
Graafian follicle in a section of an ovary of a mouse from the PBS control group showing 
antral space (black arrow), ovum and its nucleus and nucleolus (green arrowhead), which 
was surrounded by corona radiate cells (black arrowhead). A well-defined zone of 
granulosa cells with a demarcating basement membrane was observed (red arrowhead). 
Marked degenerative changes were observed in the ooplasm of ovaries collected from 
mice treated with compounds 2 (C), 1 (D), 3 (E) and 4 (F) (C-F Bar= 200 µm), and 1 + 
CFA (G) (Bar= 400 µm). In the majority of treated ovaries the ooplasm was found to have 
shrunk and shifted to one side (black arrows), and did not contain a visible nucleus or 
nucleolus. Many vacant areas were observed in the stroma of the treated ovaries (black 
arrowhead) some of which were full of fluid (green arrowhead, C). 
  
Table 3.3. Effect of LHRH vaccine candidates on folliculogenesis in mouse ovaries. 
Type	  of	  
follicle 
PBS 1	  (Th(K-­‐
LP)LHRH)+	  
CFA 
1	  (Th(K-­‐
LP)LHRH) 
2	  (LHRH(K-­‐
LP)Th) 
3	  (LHRH(K-­‐
Th)LP) 
4	  (Th(K-­‐
LHRH)LP) 
Corpus	  
luteum	  
2.79	  ±	  0.39	   2.25	  ±	  0.40	   3.38	  ±	  0.49	   3.25	  ±	  0.90	   3.44	  ±	  0.81	   3.13	  ±	  0.53	  
Antral	  	   6.33	  ±	  0.68	   5.00	  ±	  0.63	   4.06	  ±	  0.54	   5.63	  ±	  1.05	   5.00	  ±	  0.43	   5.38	  ±	  0.47	  
Atretic	   1.67	  ±	  0.21	   6.56	  ±	  1.29	  ***	   4.94	  ±	  0.82*	   4.75	  ±	  0.89	   4.20	  ±	  1.08	   6.63	  ±	  1.41**	  
Antral	   count	  
ratio	  
79.17%	   43.24%	   45.10%	   54.22%	   54.35%	   44.79%	  
Atretic	  
count	  ratio	  
20.83%	   56.76%	   54.90%	   45.78%	   45.65%	   55.21%	  
Values are expressed as Mean ± SEM.  
* Values are significantly different (*p < 0.05, **p < 0.01, ***p < 0.001) by one-way ANOVA, 
and Dunnet’s multiple comparison post hoc tests when compared with PBS control. 
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3.4 Conclusion 
Four self-adjuvanting LHRH vaccine candidates were produced to investigate the effect of 
their structural arrangement on the activity of anti-LHRH vaccine candidates. These 
constructs stimulated significant anti-LHRH antibody titres after the second booster (third 
dose) compared to PBS without the need for an additional adjuvant. It was also shown that 
a third dose was required to elicit a significant immune response. The structure-activity 
relationship studies revealed that constructs with LHRH on either the N-terminus 
(constructs 2 and 3) or on the branch between either termini (construct 4), induced higher 
immunogenicity against LHRH than the construct with LHRH at the C-terminus (1). The 
lack of bulky residues in the N-terminus of constructs 2, 3, and 4 may have contributed to 
this observation. Immunisation with any of the four LHRH vaccine candidates disrupted 
ovarian follicular development in mice. These constructs were non-toxic to normal PBMCs 
and no significant haemolytic effect was observed at concentrations higher than the 
administered dose.  
 
The four vaccine candidates induced significant antiproliferative effects on the LHRH 
receptor positive LNCaP cell line, which is beneficial for the treatment of hormone-
dependent prostate cancers. The immunogenic and biological properties of the designed 
vaccine candidates were dependent on the free N-terminus of the LHRH epitope. This 
study demonstrated that vaccination with these anti-LHRH vaccine constructs led to a 
marked immune response. This effect was confirmed by observing changes in the ovarian 
morphology of treated mice. The ability to stimulate an anti-hapten immune response 
confirms the viability of our synthetic strategy for developing peptide vaccines. 
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Chapter 4: Synthesis and characterisation of dendritic anti-LHRH 
vaccine candidates 
4.1 Introduction 
Previous studies have proven that spatial arrangement dramatically affects 
immunogenicity of the vaccine candidates. In order to improve the immunogenicity, four 
LHRH vaccine candidates were designed and synthesised using three components: a self-
adjuvanting LP, a MAP system and peptide epitopes. This system has been used in many 
peptide-based subunit vaccine studies and has shown its potential in vaccine 
development. A poly-lysine core as a multiple antigen peptide (MAP) system carries four 
synthetic peptide epitopes. MAP system has been shown to induce significant and long-
term antibody response in vaccine studies against Malaria [142, 143].  
 
In addition, four copies of a universal immunogenic T helper epitopes from L chain of the 
influenza virus hemagglutinin (GALNNRFQIKGVELKS) as well as four copies of LHRH 
peptide in different lengths, constituted four constructs with different configuration. The T 
helper epitope is essential to facilitate B cell activation providing promiscuous binding to 
human MHC class II, which is variable in individual animals and humans. The two lengths 
of B cell epitopes were, full LHRH sequence (EHWSYGLRPG) and truncated LHRH 
(GLRPG). The sixth to tenth amino acid of LHRH was reported to give effective LHRH 
specific antibody binding affinity in a previous study [71]. The discovery of this minimal 
LHRH B cell epitope prompted us to examine the antigen potency in a MAP system 
(peptide sequence 1’, 2’, 3’ and 4’, Figure 4.1). Their immunogenicity was examined in the 
BALB/c mouse model. An antigens uptake study was performed to investigate the 
interaction between the four constructs and DCs and macrophages using flow cytometry. 
 
Standard solid-phase peptide synthesis (SPPS) is widely used in peptide-based vaccine 
development. This method is more suitable for synthesis of peptide sequences with less 
than 50 amino acids [144]. This is due to the aggregation of long peptides and by-product 
accumulation on solid-beads that results in low yields after purification [144, 145]. To 
address the problems, a copper (I)-catalysed alkyne azide 1,3-dipolar cycloaddition 
(CuAAC) or ‘click’ reaction can be alternatively used to give a higher yield in a shorter time 
period.  In the CuAAC reaction a terminal alkyne is specifically conjugated to an azide 
functional group using copper (I) as a catalyst to form 1,2,3 triazole rings [145-148]. One of 
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the advantages of the CuAAC reaction is the high selectivity of terminal azide for the 
alkyne functional groups. Unprotected peptide sequences containing terminal azide/alkyne 
can be liganded via click reaction [149]. The other advantage of the click reaction is easy 
modification of conditions, for example, use of different reaction media or variable sources 
of copper. In addition, triazole rings formed from azide-alkyene cycloaddition have been 
shown to be more resistant to proteases than the usual amide bond existing in peptides 
[150]. In a previous study conducted by Newsome et al. in 1983 triazole analogues were 
used and a low immunogenicity of the compounds was reported [151]. A research 
conducted by Oldham et al. showed a carbohydrate block conjugated with a series length 
of alkyl chain via CuAAc reaction and these compounds, containing 1,2,3-triazole, were 
examined for their cytotoxicity, the level of apoptosis and necrosis that they induce. Their 
results showed that triazole compounds, especially with long alkyl chain (12 carbons), 
were non-toxic in animals [152]. Skwarczynski et al. carried out a CuAAC reaction using a 
polylysine core in the system with a terminal alkyene conjugated with an azidated terminal 
peptide sequence [149]. The reaction conditions were set up in DMF at 50°C. Compounds 
synthesised through click reaction were later proved to be an effective immunogen in mice 
[131, 149, 153]. Thus, the CuAAc reaction was used to build dendritic structures 5, 6, 7 
and 8.  
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Figure 4.1. A) Synthesis of vaccine candidates. Compounds 5-8 were synthesised 
via the azide-alkyne cycloaddition reaction. B) Schematic structures of LHRH 
vaccine candidates 5-8. All the peptide sequences were conjugated to the poly-
lysine throught N-terminus. 
4.2 Materials and methods 
General 
Chemicals used in the peptide synthesis, methods of characterisation including ESI-MS, 
preparative HPLC, DLS, and biological studies such as splenocyte isolation, processing 
and uptake assay, animal immunisation study and ELISA were described in Chapter 3.  
4-pentynoic acid was purchased from Sigma Aldrich (Australia). Azidoacetic acid was 
synthesised according to Brabez’s method [154].  
 
Synthesis of four peptide azide epitopes and LP alkyne. 
Peptide sequences with azide (1’, 2’, 3’, 4’) were synthesised using Fmoc chemistry 
assisted by microwave via standard solid phase stepwise synthesis. Four peptide azide 
epitopes were synthesised on 0.2 mmol scale (0.59mmol/g substitution) with 4.2 equiv 
amino acids activated by 0.5M HATU/DMF solution (4 equiv.) and DIPEA (6 equiv.). The 
azideoacetic acid was coupled at the final amino acid using the same equiv of HATU and 
DIPEA as coupling amino acids but the reaction was left at room temperature overnight. 
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Crude peptides were cleaved from the resin using a solution of 95% TFA, 2.5% 
triisopropylsilane and 2.5% water for 2 h.  
Alkylated LP was synthesised via SPPS with 0.1 mmol scale on rink amide resin. Amino 
acids (4.2 equiv.) were activated as described above. The last amino acid (8.4 equiv.) was 
coupled using 8 equiv of HATU and 12 equiv of DIPEA. Pentynoic acid (4.2 equiv.) was 
then coupled at the final amino acid overnight at room temperature. Cleavage of crude 
peptide was the same method as above.  
Three different methods were used for the purification of different peptide azide epitopes 
and LP alkyne as follows: 
Method 1: a gradient of 0% to 50% solvent B over 50 min at a flow rate of 20 mL/min; 
Method 2: a gradient of 30% to 70% solvent B over 40 min at a flow rate of 20 mL/min; 
Method 3: a gradient of 35% to 75% solvent B over 75 min at a flow rate of 10 mL/min. 
The fractions collected from preparative RP-HPLC were checked by ESI-MS for presence 
of the product, and analytical RP-HPLC using a Grace Vydac C4 column (5 µm, 4.6 x 250 
mm) set at a gradient of 0 to 100% with solvent B over 30 min and a flow rate of 1 mL/min 
to check the purity. Pure fractions were lyophilised to obtain the products. 
  
N3-Th-LHRH  [1’] Yield: 28% (method 1); analytical HPLC: tR = 12.6 min ESI-MS: [M + 
2H]2+ m/z 1520 (calc 1520), [M + 3H]3+ m/z 1014 (calc 1014), [M + 4H]4+ m/z 761 (calc 
761); MW 3039.37 g/mol. 
 
N3-Th-LHRH(6-10) [2’] Yield: 25% (method 3); analytical HPLC: tR = 12.4 min ESI-MS: [M 
+ 2H]2+ m/z 1169 (calc 1169); [M + 3H]3+ m/z 779 (calc 779), [M + 4H]4+ m/z 585 (calc 
585), MW 2336.65 g/mol. 
 
N3-LHRH-Th  [3’] Yield: 28% (method 1); HPLC: tR = 12.8 min ESI-MS: [M + 2H]2+ m/z 
1520 (calc 1520), [M + 3H]3+ m/z 1014 (calc 1014), [M + 4H]4+ m/z 761 (calc 761); MW 
3039.37 g/mol. 
 
N3-LHRH(6-10)-Th [4’] Yield: 26% (method 1); HPLC: tR = 12.4 min ESI-MS: [M + 2H]2+ 
m/z 1170 (calc 1169); [M + 3H]3+ m/z 780 (calc 779), [M + 4H]4+ m/z 585 (calc 585), MW 
2336.65 g/mol.  
 
(Alkyl)4-polyK2-LP [5’] Yield: 26% (method 2); analytical HPLC: tR = 21.1 21.6 min ESI-
MS: [M + 2H]2+ m/z 959 (calc 958); [M + 3H]3+ m/z 639 (calc 639), MW 1914.59 g/mol. 
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LHRH-ThNH2 [10] Yield:  33% (method 3); HPLC: tR = 13 min ESI-MS; [M + 3H]3+ m/z 986 
(calc 986), [M + 4H]4+ m/z 740 (calc 740), [M + 5H]5+ m/z 592 (calc 592), MW 2956 g/mol. 
 
Click reaction 
The Click reaction was carried out according to a procedure described by Skwarczynski et 
al. [153]. Four dendritic structures (5, 6, 7, 8) were synthesised using azide-alkyne 
cycloaddition as illustrated in Figure 4.1a. Through azide-alkyne cycloaddition, azide and 
alkyne form a 1,2,3-triazole ring. Azidoacetic acid was coupled to the N-terminus of all four 
peptide epitopes (R1) to produce four LHRH epitope building blocks (1, 2, 3 and 4). 
Structure 5’ was synthesised using a lipopeptide connected with a polylysine core where 
the N-terminus was modified by addition of pentanoic acid.  
 
Structure 5’ (1.57 µmol, 3 mg) was dissolved in 1 ml of DMF and mixed with peptide azide 
1’ (7.85 µmol, 5 equiv.) prepared in 1 ml of DMF. Copper wires (60–80 mg) were added to 
the mixture as a catalyst. The mixture was filled in with nitrogen, stirring at 50°C in an oil 
bath. The same reaction conditions were also applied in synthesis of compound 6, 7 and 8 
with peptide azide 2’, 3’ and 4’. The reaction was monitored by ESLD-HPLC until 
completion. DMF was removed in vacuum by co-evaporation. Solvent A and B (50%) were 
utilised to dissolve the crude compounds. Purification was performed by preparative HPLC 
to obtain compound 5, 6, 7 and 8. 
 
Compound 5. Yield:  18% (method 3); analytical HPLC: tR = 16.3 min ESI-MS: [M + 8H]8+ 
m/z 1409 (calc 1407),  [M + 9H]9+ m/z 1252 (calc 1251),  [M + 10H]10+ m/z 1127 (calc 
1126),  [M + 11H]11+ m/z 1025 (calc 1023), [M + 12H]12+ m/z 1252 (calc 1251),  [M + 
13H]13+ m/z 868 (calc 866), [M + 14H]14+ m/z 805 (calc 804), [M + 15H]15+ m/z 756 (calc 
750), [M + 16H]16+ m/z 705 (calc 703),  MW 14070.03 g/mol. 
 
Compound 6. Yield: 10.6% (method 3); analytical HPLC: tR = 16.5 min ESI-MS: [M + 6H]6+ 
m/z 1878 (calc 1876),  [M + 7H]7+ m/z 1610 (calc 1608),  [M + 8H]8+ m/z 1417 (calc 1407),  
[M + 9H]9+ m/z 1253 (calc 1251),  [M + 10H]10+ m/z 1128 (calc 1126),  [M + 11H]11+ m/z 
1025 (calc 1023), [M + 12H]12+ m/z 939 (calc 938),  [M + 13H]13+ m/z 867 (calc 866), [M + 
14H]14+ m/z 805 (calc 804), [M + 15H]15+ m/z 752 (calc 750), MW 11259.17 g/mol. 
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Compound 7. Yield: 20% (method 3); HPLC: tR = 16.4 min; ESI-MS: [M + 10H]10+ m/z 1408 
(calc 1408),  [M + 11H]11+ m/z  (calc 1280), [M + 12H]12+ m/z 1174 (calc 1173),  [M + 
13H]13+ m/z 1084 (calc 1083), [M + 14H]14+ m/z 1005 (calc 1006), [M + 15H]15+ m/z 939 
(calc 939), [M + 16H]16+ m/z 881 (calc 880), [M + 17H]17+ m/z 836 (calc 828),  [M + 18H]18+ 
m/z 783 (calc 782),  [M + 19H]19+ m/z 742 (calc 741),  [M + 20H]20+ m/z 705 (calc 704),  
MW 14070.03 g/mol. 
 
Compound 8. Yield: 4.5%(method 3); analytical HPLC: tR = 17.3 min ESI-MS: [M + 8H]8+ 
m/z 1409 (calc 1407),  [M + 9H]9+ m/z 1252 (calc 1251),  [M + 10H]10+ m/z 1127 (calc 
1126),  [M + 11H]11+ m/z 1025 (calc 1023), [M + 12H]12+ m/z 940 (calc 938),  [M + 13H]13+ 
m/z 868 (calc 866), [M + 14H]14+ m/z 805 (calc 804), [M + 15H]15+ m/z 756 (calc 750), [M + 
16H]16+ m/z 705 (calc 703),  MW 11259.17 g/mol. 
 
Transmission electron microscopy 
Samples were prepared at 50 ug in 50 uL (1ug/uL). A JEM-1010 TEM was used in this 
study, operating at 100 kV. The samples were prepared in a 200 mesh carbon coated 
grids for 2 min. Excess liquid was wicked away using filter paper. Microimages were taken 
to analyse particle size and shape using AnalySIS® software. The images were analysed 
using Image J (1.48v, Natinoal Institutes of Health, USA). 
 
Animal study 
Compounds 5, 6, 7 and 8 were prepared in sterile PBS. Three intramuscular injections 
were performed on 36 BALB/c female mice (6 mice per group). Each injection was 
undertaken at four-week intervals. Compound 3 (LHRH-K(Th)-LP) proved successful for 
producing high immunogenicity (Chapter 3). Therefore, it was coadmiminstred with CFA to 
be used as positive control. All mice were sacrificed after experiment to remove their 
ovaries. Ovaries were weighed using a microbalance (Sartorius, model no. ME5). Murine 
ovaries were fixed in 10% buffered neutral formalin and were dehydrated through a series 
of graded ethanol baths and stored in 70% EtOH.  
4.3 Results and discussion 
Synthesis 
An attempt was made for the synthesis of lipopeptide (S-S-C16-C16) using three lysine 
residues as the core (Figure 4.2 left). The synthesis was successful but there were 
difficulties during purification due to hydrophobicity of the structure. Thus, the lipopeptide 
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part was modified by adding four lysine groups in order to provide extra amine groups 
(Figure 4.2 right). These amine groups were proposed to increase hydrophilicity of the 
whole structure to facilitate the purification process and improve the yield.  
 
MAP has been widely used in vaccine development to improve the immunogenicity of the 
peptides [116, 155]. It was demonstrated that high levels of antibody titres were produced 
by immunising rams with a lipidic self-adjuvanting structure construct designed in a system 
carrying two copies of LHRH and two copies of a ram-specific T helper epitope [85]. 
Furthermore, previous studies showed that a universal T helper epitope was essential to 
boost the anti-LHRH immune response. Herrera et al. reported that a combination of B cell 
epitope with T helper epitope in a structure increased potency of an anti-malaria 
immunogen [155]. To enhance the immune response and to compare to the most 
promising structure (compound 3) from chapter 3, a strategy was adapted to present T 
helper epitope-B cell epitope or B cell-T helper epitope on a polylysine core carrier 
conjugated to a LP. Thus, a modified LP (Figure 4.2 right) with four free amine groups was 
synthesised to overcome the difficulties of the purification process.  
 
Figure 4.2. Modification of new lipid core peptide structure. The lipopeptide with 
three Lys residues (left) was modified by addition of 4 lysine groups (right) to 
facilitate purification by increasing the hydrophilicity of the compounds.  
The four final constructs are shown in Figure 4.1. In the design of the four different 
epitopes, apart from having T helper epitope and B cell epitope in different positions, two 
different lengths of the B cell epitope were used; the whole LHRH sequence 
(EHWSYGLRPG) and a truncated B cell epitope, LHRH6-10 (GLRPG). Zeng et al. showed 
that a strong anti-LHRH antibody response was produced by a synthetic LHRH6-10-
incorporated peptide vaccine. This construct successfully rendered female mice infertile 
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[125]. 
Synthesis of the four compounds using Fmoc and Boc chemistry via linear strategy 
(stepwise synthesis) was initially attempted but was unsuccessful due to high level of 
impurities caused by the long epitope (>20 amino acids) that lead to difficulties during 
purification. To overcome the difficulty of synthesis, a convergent strategy was adopted. 
Through this strategy the four designed epitopes were conjugated to the LP via azide-
alkyne cycloaddtion with copper as catalyst to obtain the desired compounds (5-8). This 
method has shown to be successful in the synthesis of other vaccine candidates [153]. 
The click reaction was performed in DMF solution at 50°C under nitrogen gas and 
monitored by analytical HPLC and ESI-MS. The click reaction was used to achieve the 
four constructs 5, 6, 7 and 8 with different durations of time (16 - 22 h). Four compounds 
were characterised (analytical HPLC and ESI-MS) and purified (preparative HPLC).  
 
Dynamic light scattering (DLS) 
The measurement of particle size was carried out immedatly afte dissolving the 
compounds in sterile PBS at room temperature. Amphiphilic peptides often have a 
tendency to self-assemble into nano or microparticles in solution [131]. The compounds 
presented here possess hydrophilic (LHRH and influenza haemaglutinin HA2 sequence) 
and hydrophobic (LP moiety) properties and thus were expected to form particles in 
solution. To investigate monodispersity of the compounds, the ideal polydispersity index 
(PDI) valuce should be below 0.2. The higher value of PDI, close to 1, represents to 
varable particle size distrubtion and/or aggregation. DLS measurements showed a wide 
distribution of particle sizes, resulting in a high PDI, close to 1. All compounds tended to 
form large nanoparticles or microparticles with various sizes typically above 300 nm (Table 
4.1.). 
 
Table 4.1. Particle size analyses of compounds 5-8. 
Method Size (nm) 
 5 6 7 8 
     
PDI 0.474 0.575 0.808 0.506 
DLS <300 >300 >300 =300 
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Transmission electron microscopy (TEM) 
The particle size of four compounds was measured and morphology was observed by 
TEM (Figures 4.3 and 4.4, 500 and 200 nm scale bar). The particle sizes of the four 
compounds observed covered a wide range (< 10 nm, 20-130 nm, > 200 nm). Also, large 
aggregates were observed in all images. An image of compound 6 at a 500 nm bar scale 
(Figure 4.3B), showed fibre-like particles. For more clarity a zoomed-in image of each 
compound is shown in Figure 4.4 at a 200 nm bar scale. In Figure 4.4B, compound 6 
showed particles over 200 nm with non-unified aggregates. In addition, sphere-shaped 
particles with variable size range (5 nm-130 nm) were seen in all images (Figures 4.3 and 
4.4). In agreement with the DLS results, some particles over 300 nm were observed. Also, 
small particles <10 nm and 20-130 nm were observed in different images. Self-assembled 
peptides have been reported to form particles at different sizes, 25 nm or 40-50 nm and 
they have been shown to produce a strong IgG immune response [132, 133]. Particle size 
distribution histograms (Figure A10) and figures of DLS (Figure A9) were attached in 
appendix B. All compounds showed particle size below 20 nm from histograms (Figure 
A10). No correlation was found between the results of DLS and TEM. However, there are 
reports in the literature on the preferential uptake of virus-sized particles (20–200 nm) by 
DCs and even larger particles (0.5–5 µm) by macrophages [156]. This can explain the 
immunogenicity of these vaccine candidates in spite of forming particles with different 
sizes.  
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Figure 4.3. TEM images showing the particles formed by four dendritic vaccine 
candidates, 5 (A), 6 (B), 7 (C) and 8 (D) at 500 nm scale. Particle size observed from 
each compound: compound 5 (20-75 nm), compound 6 (10-95 nm, >500 nm), 
compound 7 (8-10 nm, 64-80 nm), compound 8 (18-26 nm, 282 nm, 773 nm). 
C D 
B A 
500 nm 500 nm 
500 nm 500 nm 
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Figure 4.4. TEM images of four dendritic vaccine candidates, 5 (A), 6 (B), 7(C) and 8 
(D) at 200 nm scale. Particle size observed from each compound was as follows: 
compound 5 (57-71 nm), compound 6 (>200 nm), compound 7 (5-8 nm), and 
compound 8 (26-44 nm). 
 
Uptake of vaccine constructs by dendritic cells and macrophages 
An uptake study was performed by culturing compounds (5, 6, 7, 8) and a control peptide 
(LHRH-ThNH2 incorporating LHRH with the T helper epitope), with murine DCs and 
macrophages isolated from spleen (Figure 4.5a and b). Calculation of percentage is based 
on positive control as 100% and compared to examined compounds uptake by DCs or 
macrophages. All compounds demonstrated significant uptake by DCs with no statistical 
difference between them. Similarly, treatment of macrophages with the compounds 
revealed significant uptake of all compounds. Specifically, up to 92% of compound 7 was 
A B 
C D 
200 nm 
200 nm 
200 nm 
200 nm 
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uptaken by macrophages (p < 0.05). However, in spite of the high level of uptake of all 
compounds by DCs and macrophages, vaccine candidates 7 and 8 did not produce 
significant immune responses when they were tested for binding affinity to LHRH peptide 
(Figure 4.6a, p > 0.05). These compounds showed production of antibodies with significant 
binding to a structure containing both B cell and T helper epitopes. One explanation is that 
DCs could recognise the structure incorporating both epitopes, Th-LHRH or Th-LHRH (6-
10) (Figure 4.6a). Therefore, plausibly either the whole structure or only the T helper 
epitope was displayed on MHC II to be presented to B cells.  
 
 
Figure 4.5. Uptake of compounds 5, 6, 7 and 8 by a) dendritic cells, and b) 
macrophages. Eight LHRH peptide vaccine candidates (50 µM) and a control group, 
LHRH-Th, were incubated with antigen presenting cells (DCs and macrophages) 
overnight at 37°C. PBS and dextran were the negative and positive controls, 
respectively. Data presented are means (± SEM) from separate experiments 
performed in triplicate (*, p < 0.05; **, p < 0.01; ***, p < 0.001).   
 
Immunogenicity of vaccine constructs 
Antisera were collected at day 27, 56 and 66 from immunised mice and examined using 
ELISA. LHRH IgG antibody titres were measured for each day (Figure 4.6a and b days 27, 
56, and Figure 4.7a day 66). At days 27 and 56, only the positive control (CFA+ compound 
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3, described in Chapter 3) demonstrated LHRH immune response. No antibody production 
was observed in the other treated groups.  
 
After a primary injection and two boosts, LHRH antibodies were generated in the groups of 
mice treated with constructs 6, 7 and 8 (Figure 4.7). The antibody titres of the samples 
collected from mice treated with 7 and 8 did not show any statistical differences compared 
to the negative control (p > 0.05). Only the group of mice vaccinated with compound 6 
showed significant levels of antibody titres compared to the negative control (p < 0.05) 
producing similar immunogenicity to the positive control administered with CFA. LHRH 
antibody titre produced from compound 6 was 100 times higher than that of groups treated 
with compound 7 and 8 after three injections (Figure 4.7, p < 0.001). 
 
 
 
Figure 4.6. Mice LHRH sera from six groups (PBS negative control, positive control, 
groups treated with compounds 5, 6, 7 and 8. a) mice antisera collected after 
primary injection on day 27. b) mice antisera collected after second injection. The 
results are shown as the mean of antibody titres directed to LHRH measured using 
ELISA. Statistical analysis was performed using a one-way ANOVA followed by 
Tukey’s post hoc test (***, p < 0.001). 
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Figure 4.7. Mice LHRH serums from six groups (PBS, positive control, compounds 5-
8) after the final bleed on day 66 were examined by coating the plate with LHRH 
measured using ELISA. Statistical analysis was performed using a one-way ANOVA 
followed by Tukey’s post hoc test (***, p < 0.001).   
Truncated LHRH epitope (GLAPG), compound 6, also produced significant immune 
response. Two different B cell-T helper epitope combinations (LHRH-Th and LHRH6-10-
Th) were synthesised linked to a LP system. This was performed to investigate the 
immunogenicity of the LHRH epitope of different lengths with Th combination in the 
designed system. The results suggested that five amino acids (GLAPG) from LHRH were 
sufficient to be recognised by APCs and produce an immune response.  Compounds 7 
and 8, which the LHRH epitopes embedded in between the Th epitope and MAP system, 
were not presented significant immune response against LHRH, which suggests that the 
exposure of LHRH to APCs is the key in these structures to trigger hight LHRH antibody 
production.   
 
Weight of mice ovaries 
The average weights of the ovaries of the six groups of mice were measured to investigate 
the atrophic effect of LHRH antibody on the ovaries (Figure 4.8). The positive control 
group showed a significant reduction in ovary weight (p < 0.05). The average weight of the 
ovaries from groups of mice treated with compounds 7 and 8 was significantly less than 
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that of the negative control (p < 0.05). However, no difference was observed between four 
treatment groups (p < 0.05). These results were inconsistent with the achieved antibody 
titres, which was not significant for these groups of mice compared to the negative control 
(p > 0.05). Although, average weight of ovaries from group 7 and 8 are significantly lower 
than negative control but not sufficient evidence to support the antrophy effect caused by 
LHRH antibodies. This may require   
                                
Figure 4.8. Weight of mice ovaries treated with immunogens 5-8 and a positive 
control. Statistical analysis was performed using a one-way ANOVA followed by 
Tukey’s post hoc test (**, p < 0.01, ***, p < 0.001). 
 
4.4 Conclusion 
In this study, four LHRH vaccine candidates were successfully synthesised via click 
reaction. The convergent strategy adopted as the synthesis approach allowed conjugation 
of two units via azide-alkyne cycloaddition and facilitated the purification process. Four 
compounds were synthesised based on a system in a dendritic manner carrying two 
different lengths of LHRH with Th combination and their immunogenicity were examined in 
BALB/c mice with a scheduled primary injection and two boosts. These compounds 
demonstrated a wide range of particle size (10-1000 nm). A high percentage uptake by 
DCs and macrophages was observed. However, this high uptake by compounds 7 and 8 
was not translated into a significant immune response against LHRH in a mouse model. 
On the other hand, compound 6 demonstrated high antibody production, which was a 
promising finding for further studies in vaccine development; however, further modification 
of the vaccine structure may be required. 
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Chapter 5: Conclusion 
The majority of this thesis focused on design, synthesis and biological evaluation of anti-
LHRH vaccine candidates based on lipopeptide delivery systems. The major aim was to 
improve the immunogenicity of the vaccine candidates in vivo without addition of an 
external adjuvant. A library of compounds was synthesised and examined by incorporating 
the same B cell epitope, T cell epitope and a self-adjuvanting system but with different 
spatial arrangements. Another series of compounds was synthesised based on a system 
of  dendritic structures, using either full-length or truncated sequence of LHRH. Both set of 
compounds were then tested for immunogenicity in BALB/c mice using a primary injection 
and two boosts. A monosaccharide-based compound was also synthesised and 
characterised.  
 
In Chapter 2, an attempt to synthesise a galactose core as a scaffold bearing four LHRH 
epitopes and a LP was successful. However, difficulty in purification resulted in a very low 
yield. In order to achieve a more efficient carbohydrate scaffold synthesis, an optimisation 
of the method is necessary. A quick and optimised convergent approach of carbohydrate 
scaffold synthesis has been achieved in building a GAS vaccine candidate just recently. 
This can be trialled for the synthesis of LHRH vaccine candidates with different 
carbohydrate moieties in order to improve the synthesis process. 
 
As discussed in Chapter 3, four branched anti-LHRH vaccine candidates, conjugated to a 
self-adjuvanting lipopeptide moiety, were able to induce potent LHRH-specific immune 
responses without requirement of an external adjuvant. Histological changes in ovaries 
demonstrated production of anti-LHRH antibodies that could successfully disturb the 
hypothalamic–pituitary–gonadal axis by decreasing the level of circulating LHRH. 
However, three injections were required to give significant antibody titres. This triggers an 
interest to further modify these structures and investigate new candidates that can produce 
persistent antibody titre. Regular monitoring of the antibody titre in vivo and birth rate will 
give a clue of the efficacy of these vaccine candidates.  
 
Moreover, the T helper epitope was used in all anti-LHRH vaccine constructs to provide 
strong immunogens. A future direction for developing anti-LHRH persistent antibodies 
could involve inclusion of another T helper epitope to provide a longer lasting immune 
response.  
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Modification in the spatial arrangement of the four branched compounds resulted in the 
induction of variable levels of antibody titre. Compound 3 (LHRH-(K-Th)-LP) demonstrated 
the highest antibody titres in the immunological studies. All compounds showed high 
polydispersity in particle size. Despite the high uptake of compound 3 by DCs and 
macrophages, the majority of particles were over 300 nm. It has been shown that DCs 
preferentially uptake virus-sized particles (20–200 nm) whereas macrophages uptake 
larger particles (0.5–5 µm) [156]. The crucial size of particles for eliciting adjuvant activity 
has been reported by many researchers. However, there are conflicting reports on the size 
of particle-based vaccine candidates and the resultant immune responses. In this study, 
the interaction between vaccine structures and immune cell receptors remained unknown. 
Thus, further research is suggested to reveal the mechanism of uptake using a 
competition study (blocking specific receptors) to discover the interaction between 
compounds and APCs. The four branched compounds were shown to be non-toxic to 
PBMCs. Although some degree of haemolysis was observed at high concentrations in 
vitro, no sign of haemolysis was detected in mice after intramuscular administration. 
However, the in vitro haemolysis assay suggests that intravenous administration of these 
compounds, or possibly those compounds with similar structure, should proceed with 
caution if this need arises.  
 
Another significant finding of this study was the antiproliferative effect of the branched 
vaccine candidates on LNCaP, hormone-sensitive, LHRH receptor (+) cancer cells. It 
would be interesting to evaluate the in vivo antiproliferative effect of these compounds by 
carrying out a tumour challenge in an immunised mouse model in the future. 
 
In Chapter 4, the system was proposed to carry four copies of LHRH-Th epitopes to 
achieve strong immunity. A convergent strategy was applied to synthesise a library of 
dendritic LHRH vaccine candidates that overcame the challenge caused by the linear 
synthesis approach. Three dendritic vaccine candidates demonstrated significant IgG 
response against LHRH without administration of CFA. Compound 6 (LHRH6-10Th-
PolyK2-LP), incorporating a truncated LHRH sequence, LHRH6-10 (GLRPG), at the N-
terminus, produced the most potent IgG response against LHRH and other LHRH-
containing coating antigens. The key finding from this chapter was that the compound with 
only five C-terminal amino acids of the LHRH B cell epitope, showed a high immune 
response in this system. This is an important finding towards developing LHRH vaccines. 
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Also, the other two dendritic structures, ThLHRH-polyK2-LP and ThLHRH6-10-polyK2-LP, 
containing T helper epitopes conjugated to the N-terminus of full-length and truncated 
LHRH, were still able to produce an IgG response against LHRH and all coating antigens. 
Dimer LHRH6-10 with a T helper epitope could be used as a model structure in future 
studies for development of new LHRH vaccines or different delivery systems such as 
polymers. Manipulation and modification of hydrophobicity and hydrophilicity to form self-
assembling particles by introducing hydrophobic T helper epitopes or hydrophobic self-
adjuvanting moieties in the structure are also suggested for improving the immunogenicity 
of the current structures for future study.  
 
Overall, the ultimate goal to develop vaccines able to elicit anti-LHRH immune response 
without additional adjuvants was achieved. Structures with different spatial arrangements 
or systems carrying combined LHRH-T helper epitopes were shown to have the potential 
to be used in the development of safe and efficient anti-LHRH vaccines.  
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Appendix A 
 
 
Figure A1. Physic characterization of compound (2): NMR and MS spectra. 
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Figure A2. Physico-characterization of compound (4): NMR and MS spectra. 
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Figure A3. Physic characterization of compound (6): NMR and MS spectra. 
 
 
 
 
 93 
 
Figure A4. Chemical structure of Dde-C16. 
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Figure A5. Mass spectra of and analytical HPLC of compound 1 examined with two 
methods: 1) 0 – 100 % solvent B2, over 30 min and 2) 0 – 100 %, Methanol, over 30 
min. 
 +Q1: 4.981 to 5.323 min from Sample 1 (TuneSampleID) of MT20141002114042.wiff (Ion Spray) Max. 2.8e6 cps.
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Figure A6. Mass spectra of and analytical HPLC of compound 2 examined with two 
methods: 1) 0 – 100 % solvent B2, over 30 min and 2) 0 – 100 %, Methanol, over 30 
min. 
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Figure A7. Mass spectra of and analytical HPLC of compound 3 examined with two 
methods: 1) 0 – 100 % solvent B2, over 30 min and 2) 0 – 100 %, Methanol, over 30 
min. 
 +Q1: 1.254 to 1.455 min from Sample 1 (TuneSampleID) of MT20130131193018.wiff (Ion Spray) Max. 4.2e5 cps.
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Figure A8. Mass spectra of and analytical HPLC of compound 4 examined with two 
methods: 1) 0 – 100 % solvent B2, over 30 min and 2) 0 – 100 %, Methanol, over 30 
min. 
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Appendix B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9. Particle size measurement of compound 5-8 by dynamic light scattering 
after multiple measurements. 
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Figure A10. Histograms of particle size distribution for compound 5-8. 
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